<SEC-DOCUMENT>0001213900-26-054634.txt : 20260512
<SEC-HEADER>0001213900-26-054634.hdr.sgml : 20260512
<ACCEPTANCE-DATETIME>20260511182629
ACCESSION NUMBER:		0001213900-26-054634
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260512
DATE AS OF CHANGE:		20260511

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Onconetix, Inc.
		CENTRAL INDEX KEY:			0001782107
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-295376
		FILM NUMBER:		26964922

	BUSINESS ADDRESS:	
		STREET 1:		201 E. FIFTH STREET
		STREET 2:		SUITE 1900
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45202
		BUSINESS PHONE:		513-620-4101

	MAIL ADDRESS:	
		STREET 1:		201 E. FIFTH STREET
		STREET 2:		SUITE 1900
		CITY:			CINCINNATI
		STATE:			OH
		ZIP:			45202

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Water Biotech, Inc.
		DATE OF NAME CHANGE:	20230424

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Blue Water Vaccines Inc.
		DATE OF NAME CHANGE:	20190710
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>ea0290185-424b3_onconetix.htm
<DESCRIPTION>PROSPECTUS
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>PROSPECTUS</B></FONT></TD>
    <TD STYLE="width: 50%; text-align: right; font-size: 10pt"><FONT STYLE="font-size: 10pt"><B>Filed Pursuant to Rule 424(b)(3)<BR>
Registration No. 333-295376</B></FONT></TD></TR>
  </TABLE>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0"><IMG SRC="ea029018501_img1.jpg" ALT=""></P>

<P STYLE="text-align: center; margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>25,000,000 shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus relates to
the offer and sale from time to time by Keystone Capital Partners, LLC (&ldquo;Keystone&rdquo; or the &ldquo;Selling Stockholder&rdquo;)
of up to 25,000,000 shares of common stock of Onconetix, Inc. (&ldquo;we,&rdquo; &ldquo;us,&rdquo; &ldquo;our,&rdquo; the &ldquo;Company,&rdquo;
or &ldquo;Onconetix&rdquo;), par value $0.00001 per share (the &ldquo;Common Stock&rdquo;), that have been or may be issued by us to Keystone
pursuant to that certain Common Stock ELOC Purchase Agreement, dated as of October 2, 2024, by and between us and Keystone (the &ldquo;ELOC
Purchase Agreement&rdquo;), establishing an equity line of credit (&ldquo;ELOC&rdquo;). Such shares of our Common Stock include up to
25,000,000 shares of Common Stock (assuming the shares to be issued are sold at a price of approximately $0.6771 per share, which, in
accordance with the terms of the ELOC Purchase Agreement, is equivalent to or greater than 90% of the daily volume weighted average price
(the &ldquo;VWAP&rdquo;) of the Common Stock for the five trading days immediately preceding April 24, 2026) that we may elect, in our
sole discretion, to issue and sell to Keystone, from time to time from and after the commencement date under the ELOC Purchase Agreement,
and subject to applicable stock exchange rules.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The actual number of shares
of our Common Stock issuable will vary depending on the then-current market price of shares of our Common Stock sold to the Selling Stockholder
under the ELOC Purchase Agreement, but will not exceed the number set forth in the preceding sentences unless we file an additional registration
statement under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), with the U.S. Securities and Exchange Commission
(SEC), See &ldquo;<I>The Keystone Equity Financing</I>&rdquo; for a description of the ELOC Purchase Agreement and &ldquo;<I>Selling Stockholder</I>&rdquo;
for additional information regarding Keystone.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are registering the shares
on behalf of the Selling Stockholder, to be offered and sold by it from time to time. We are not selling any securities under this prospectus,
and will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive
up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares
of our Common Stock pursuant to the ELOC Purchase Agreement at varying purchase prices after the date of this prospectus. However, the
actual proceeds from Keystone may be less than this amount depending on the number of shares of our Common Stock sold and the price at
which the shares of our Common Stock are sold. Through April 24, 2026, we have sold approximately 701,933 split-adjusted shares under
the ELOC Purchase Agreement for aggregate proceeds of approximately $8.1 million. The purchase price per share that Keystone will pay
for shares of Common Stock purchased from us under the ELOC Purchase Agreement will fluctuate based on the market price of our shares
at the time we elect to sell shares to Keystone and, further, to the extent that the Company sells shares of Common Stock under the ELOC
Purchase Agreement, substantial amounts of shares could be issued and resold, which would cause dilution and may impact the Company&rsquo;s
stock price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock is listed on The Nasdaq Capital Market under the symbol
&ldquo;ONCO.&rdquo; The last reported sale price of our Common Stock on The Nasdaq Capital Market on May 7, 2026 was $0.404 per share.
We recommend that you obtain current market quotations for our Common Stock prior to making an investment decision.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder is
an &ldquo;underwriter&rdquo; within the meaning of Section 2(a)(11) of the Securities Act. The Selling Stockholder may offer all or part
of the shares for resale from time to time through public or private transactions, at either prevailing market prices or at privately
negotiated prices. Our registration of the shares of Common Stock covered by this prospectus does not mean that the Selling Stockholder
will offer or sell any of the shares. With regard only to the shares the Selling Stockholder sells for its own behalf, the Selling Stockholder
may be deemed an &ldquo;underwriter&rdquo; within the meaning of the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;).
The Company has paid all of the registration expenses incurred in connection with the registration of the shares. We will not pay any
of the selling commissions, brokerage fees and related expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will pay the expenses
incurred in registering the shares, including legal and accounting fees. See &ldquo;<I>Plan of Distribution</I>&rdquo; on page 41 of
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Investing in our Common
Stock involves certain risks. See &ldquo;<I>Risk Factors</I>&rdquo; on page 10 of this prospectus, included in any accompanying prospectus
supplement and in the documents incorporated by reference in this prospectus for a discussion of the factors you should carefully consider
before deciding to purchase these securities.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>We may amend or supplement
this prospectus from time to time by filing amendments or supplements as required. We urge you to read the entire prospectus, any amendments
or supplements, any free writing prospectuses, and any documents incorporated by reference carefully before you make your investment decision.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">The date of this prospectus is May 7, 2026</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>TABLE OF CONTENTS</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 90%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 2%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; text-align: center; width: 8%"><B>Page</B>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_001">ABOUT THIS PROSPECTUS</A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">ii</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD><A HREF="#a_002">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">iv</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD><A HREF="#a_003">RISK FACTORS </A></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: center">10</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_004">ELOC FINANCING</A> </TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">19</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_005"><FONT STYLE="text-transform: uppercase">DESCRIPTION OF CAPITAL STOCK</FONT>&nbsp;</A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">25</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_006">SELLING STOCKHOLDERS </A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">40</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_007">PLAN OF DISTRIBUTION </A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">41</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_008">EXPERTS </A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">42</TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_009">LEGAL MATTERS </A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">42</TD></TR>
  <TR STYLE="background-color: White">
    <TD STYLE="vertical-align: bottom"><A HREF="#a_010">WHERE YOU CAN FIND MORE INFORMATION </A></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">42</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_001"></A>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is part of
a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) for the delayed
or continuous offering and sale of securities pursuant to Rule 415 under the Securities Act. This prospectus generally describes Onconetix,
Inc. and our Common Stock. The Selling Stockholder may use this registration statement to sell up to an aggregate of up to 25,000,000 shares
of our Common Stock from time to time through any means described in the section entitled &ldquo;<I>Plan of Distribution</I>.&rdquo; Our
registration of the securities covered by this prospectus does not mean that either we or the Selling Stockholder will issue, offer or
sell, as applicable, any of the securities registered hereunder. Under this registration statement, the Selling Stockholder may, from
time to time, sell the securities offered by it described in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will not receive any proceeds
from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. However, we will pay the expenses, other than underwriting
discounts and commissions, associated with the sale of shares pursuant to this prospectus. We may receive up to $25.0 million in aggregate
gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount
depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold. Through April
24, 2026, we have sold approximately 701,933 split-adjusted shares under the ELOC Purchase Agreement for aggregate proceeds of approximately
$8.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We and the Selling Stockholder,
as applicable, may deliver a prospectus supplement with this prospectus, to the extent appropriate, to update the information contained
in this prospectus. The prospectus supplement may also add, update or change information included in this prospectus. You should read
both this prospectus and any applicable prospectus supplement, together with additional information described below under the captions
&ldquo;<I>Where You Can Find More Information</I>&rdquo; and &ldquo;<I>Incorporation of Certain Information by Reference</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">No offer of these securities
will be made in any jurisdiction where the offer is not permitted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should rely only on the
information contained in or incorporated by reference in this prospectus, any accompanying prospectus supplement or in any related free
writing prospectus filed by us with the SEC. We have not authorized anyone to provide you with different information. This prospectus
and any accompanying prospectus supplement do not constitute an offer to sell or the solicitation of an offer to buy any securities other
than the securities described in this prospectus or such accompanying prospectus supplement or an offer to sell or the solicitation of
an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume that the information
appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus
is accurate only as of their respective dates. Our business, financial condition, results of operations and prospects may have changed
materially since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless the context otherwise
indicates, references in this prospectus to &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;the Company&rdquo; refer,
collectively, to Onconetix, Inc., a Delaware corporation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Unless otherwise indicated,
all share amounts and share prices disclosed herein are presented on a post-split basis, giving effect to the one-for-five (1:5) reverse
stock split (the &ldquo;Reverse Stock Split&rdquo;) of all of the outstanding shares of the Company&rsquo;s issued and outstanding Common
Stock on March 25, 2026. Any financial statements incorporated by reference into this prospectus that were filed prior to the Reverse
Stock Split present the outstanding shares on a pre-split basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below sets forth
the impact of the Reverse Stock Split on the Company&rsquo;s net loss per share of Common Stock: basic and diluted; weighted average common
shares outstanding - basic and diluted; and shares issued and outstanding, for the years ended December 31, 2025 and 2024.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">POST SPLIT</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center">YEAR ENDED</TD><TD STYLE="font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">DECEMBER 31,</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2025</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2024</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in">&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD><TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; width: 76%; text-align: left; padding-bottom: 1.5pt">Net loss applicable to common stockholders</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(15,530,937</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="width: 9%; border-bottom: Black 1.5pt solid; text-align: right">(58,897,427</TD><TD STYLE="width: 1%; padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 1.5pt">Net loss per common share &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(82.82</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD><TD STYLE="padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right">(9,121.48</TD><TD STYLE="padding-bottom: 1.5pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-indent: -0.125in; padding-left: 0.125in; text-align: left; padding-bottom: 4pt">Weighted average common shares outstanding &ndash; basic and diluted</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">187,520</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 4pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 4pt double; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 4pt double; text-align: right">6,457</TD><TD STYLE="padding-bottom: 4pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_002"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus contains
&ldquo;forward-looking statements&rdquo; within the meaning of the federal securities laws, and that involve significant risks and uncertainties.
Words such as &ldquo;may,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;predicts,&rdquo; &ldquo;potential,&rdquo;
&ldquo;continue,&rdquo; &ldquo;expects,&rdquo; &ldquo;anticipates,&rdquo; &ldquo;future,&rdquo; &ldquo;intends,&rdquo; &ldquo;plans,&rdquo;
&ldquo;believes,&rdquo; &ldquo;estimates,&rdquo; and similar expressions, as well as statements in future tense, identify forward-looking
statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications
of when such performance or results will be achieved. Forward-looking statements are based on information we have when those statements
are made or management&rsquo;s good faith belief as of that time with respect to future events and are subject to significant risks and
uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking
statements. Forward-looking statements are subject to a number of risks, uncertainties and assumptions in other documents we file from
time to time with the SEC, specifically our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current
Reports on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Important factors that could
cause such differences include, but are not limited to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our projected financial position and estimated cash burn rate;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our estimates regarding expenses, future revenues and capital requirements;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to continue as a going concern;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our need to raise substantial additional capital to fund our operations;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to commercialize or monetize Proclarix and integrate the assets and commercial operations acquired in the share exchange with Proteomedix AG (&ldquo;Proteomedix&rdquo;);</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our reliance on third parties, including Laboratory Corporation of America (&ldquo;LapCorp&rdquo;), to develop, market, distribute and sell Proclarix;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">the successful development of our commercialization capabilities, including sales and marketing capabilities.</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to consummate the transaction on a timely basis as contemplated by the Share Exchange Agreement with Realbotix, LLC (&ldquo;Realbotix&rdquo; and the &ldquo;Share Exchange Agreement&rdquo; and the transactions contemplated therein, the &ldquo;Realbotix Transaction&rdquo;) and the anticipated benefits of the Realbotix Transaction.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to maintain the necessary regulatory approvals to market and commercialize our product;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">the results of market research conducted by us or others;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to obtain and maintain intellectual property protection for our current products;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to protect our intellectual property rights and the potential for us to incur substantial costs from lawsuits to enforce or protect our intellectual property rights;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">the possibility that a third party may claim we or our third-party licensors have infringed, misappropriated, or otherwise violated their intellectual property rights and that we may incur substantial costs and be required to devote substantial time defending against claims against us;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our reliance on third parties, including manufacturers and logistics companies;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">the success of competing therapies or diagnostics and products that are or become available;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to successfully compete against current and future competitors;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">our ability to expand our organization to accommodate potential growth and our ability to attract, motivate and retain key personnel;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">the potential for us to incur substantial costs resulting from product liability lawsuits against us and the potential for these product liability lawsuits to cause us to limit our commercialization of our products;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">market acceptance of our products, the size and growth of the potential markets for our current products, and our ability to serve those markets; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">disruptions in the business of the Company or Proteomedix, which could have an adverse effect on their respective businesses and financial results.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These forward-looking statements
are subject to a number of risks, uncertainties and assumptions, including those described in &ldquo;<I>Risk Factors</I>.&rdquo; Moreover,
we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management
to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of
factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of
these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this prospectus may not occur and
actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should not rely upon
forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking
statements are reasonable, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected
in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither we nor any other person assumes
responsibility for the accuracy and completeness of the forward-looking statements. We undertake no obligation to update publicly any
forward-looking statements for any reason after the date of this prospectus to conform these statements to actual results or to changes
in our expectations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You should read this prospectus
and the documents that we reference in this prospectus and have filed with the SEC as exhibits to the registration statement of which
this prospectus forms a part with the understanding that our actual future results, levels of activity, performance and events and circumstances
may be materially different from what we expect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS SUMMARY </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>The SEC allows us to &ldquo;incorporate
by reference&rdquo; certain information that we file with the SEC, which means that we can disclose important information to you by referring
you to those documents. The information incorporated by reference is considered to be part of this prospectus, and information that we
file later with the SEC will update automatically, supplement and/or supersede the information disclosed in this prospectus. Any statement
contained in a document incorporated or deemed to be incorporated by reference in this prospectus shall be deemed to be modified or superseded
for purposes of this prospectus to the extent that a statement contained in this prospectus or in any other document that also is or is
deemed to be incorporated by reference in this prospectus modifies or supersedes such statement. Any such statement so modified or superseded
shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. You should read the following summary
together with the more detailed information regarding our company, our Common Stock and our financial statements and notes to those statements
included in this prospectus.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Our Company</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial stage
biotechnology company focused on the research, development, and commercialization of innovative solutions for oncology. Through our acquisition
of Proteomedix, which closed on December 15, 2023, we own Proclarix, an in vitro diagnostic test for prostate cancer originally developed
by Proteomedix and approved for sale in the European Union under the In Vitro Diagnostic Regulation (&ldquo;IVDR&rdquo;), which we anticipate
will be marketed in the U.S. as a lab developed test through our license agreement with LabCorp.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Since our inception in October
2018 until April 2023, when we acquired ENTADFI, we devoted substantially all of our resources to performing research and development,
undertaking preclinical studies and enabling manufacturing activities in support of our product development efforts, hiring personnel,
acquiring and developing our technology and now halted vaccine candidates, organizing and staffing our company, performing business planning,
establishing our intellectual property portfolio and raising capital to support and expand such activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">ENTADFI is an FDA-approved,
once daily pill that combines finasteride and tadalafil for the treatment of BPH, a disorder of the prostate. However, in light of (i)
the time and resources needed to continue pursuing commercialization of ENTADFI, and (ii) the Company&rsquo;s cash runway and indebtedness,
the Company abandoned commercialization of ENTADFI and no longer holds remaining inventory of the product as of December 31, 2025. In
addition, as part of cost reduction efforts and in connection with our initial pause in commercializing ENTADFI, we terminated three employees
involved with the ENTADFI program, effective April 30, 2024, with such individuals to continue assisting the Company on an as-needed,
consulting basis. Based on the circumstances surrounding ENTADFI, at June 30, 2024, the ENTADFI assets were fully impaired. Refer to Note
4 in the consolidated financial statements for the period ended December 31, 2024 for further discussion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proclarix is an easy-to-use
next generation protein-based blood test that can be done with the same sample as a patient&rsquo;s regular Prostate-Specific Antigen
(&ldquo;PSA&rdquo;) test. The PSA test is a well-established prostate specific marker that measures the concentration of PSA molecules
in a blood sample. A high level of PSA can be a sign of prostate cancer. However, PSA levels can also be elevated for many other reasons
including infections, prostate stimulation, vigorous exercise or even certain medications. PSA results can be confusing for many patients
and even physicians. It is estimated over 50% of biopsies with elevated PSA are negative or clinically insignificant resulting in an overdiagnosis
and overtreatment that impacts the physician&rsquo;s routine, our healthcare system, and the quality of patients&rsquo; lives. Approximately
10% of all men have elevated PSA levels., commonly referred to as the diagnostic &ldquo;grey zone&rdquo;, of which only 20 - 40% present
clinically with cancer. Proclarix is intended for use in diagnosing these patients where it is difficult to decide if a biopsy is necessary
to verify a potential clinically significant cancer diagnosis. Proclarix helps doctors and patients with unclear PSA test results through
the use of our proprietary Proclarix Risk Score which delivers clear and immediate diagnostic support for further treatment decisions.
No additional intervention is required, and results are available quickly. Local diagnostic laboratories can integrate this multiparametric
test into their current workflow because Proclarix assays use the enzyme-linked immunosorbent assay (ELISA) standard, which most diagnostic
laboratories are already equipped to process.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Proclarix is CE-marked and
for sale in Europe. We continue our sales efforts and expect growing revenues from sales of Proclarix in 2026 and beyond. We anticipate
these sales to offset some expenses relating to commercial scale up and development, we expect our expenses also to increase in connection
with our ongoing activities, as we:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">commercialize Proclarix;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">hire additional personnel;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">operate as a public company; </TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">obtain, maintain, expand, and protect our intellectual property portfolio; and</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">perform product validation studies in connection with a license agreement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We rely and will continue
to rely on third parties for the manufacturing of Proclarix. We have no internal manufacturing capabilities, and we will continue to rely
on third parties, of which the main suppliers are single-source suppliers, for commercial product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We do not have any products
approved for sale, aside from Proclarix. We have abandoned commercialization of ENTADFI and have destroyed our inventory of the product.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">To date, we have financed
our operations primarily with proceeds from our sale of preferred securities to seed investors, the initial public offering (&ldquo;IPO&rdquo;),
and subsequent offerings of debt and equity securities. We will continue to require significant additional capital to commercialize Proclarix,
and to fund operations for the foreseeable future. Accordingly, until such time as we can generate significant revenue, if ever, we expect
to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and to rely
on third-party resources for marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing
arrangements, or any combination of these approaches, to support our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred net losses
since inception and expect to continue to incur net losses in the foreseeable future. Our net losses may fluctuate significantly from
quarter-to-quarter and year-to-year, depending in large part on the timing of our preclinical studies, clinical trials and manufacturing
activities, our expenditures on other research and development activities and commercialization activities. As of December 31, 2025, we
had cash of approximately $5.2 million, a working capital deficit of approximately $3.1 million and an accumulated deficit of approximately
$131.2 million. During the year ended December 31, 2025, we used approximately $9.7 million in cash for operating activities. In addition,
as of April 24, 2026, our cash balance was approximately $4.2 million. We believe that our current cash balance is not sufficient to fund
its operations for one year from the date of issuance of the consolidated financial statements for the year. While such capital raises
may enable us to sustain current operations and meet existing obligations, we continue to generate recurring net operating losses and
have not yet established sustained positive cash flows to support our strategic growth initiatives. Such initiatives include the commercialization
of Proclarix and our development and commercialization of future product candidates. These factors raise substantial doubt on our ability
to continue as a going concern for one year from the date of issuance of our consolidated financial statements for the financial year
ended December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Until we generate revenue
sufficient to support self-sustaining cash flows, if ever, we will need to raise additional capital to fund our continued operations,
including our product development and commercialization activities related to our current and future products. There can be no assurance
that additional capital will be available to us on acceptable terms, or at all, or that we will ever generate revenue sufficient to provide
self-sustaining cash flows. These circumstances raise substantial doubt about our ability to continue as a going concern. The accompanying
consolidated financial statements of Onconetix, as of and for the year ended December 31, 2025, included elsewhere in this prospectus
do not include any adjustment that might be necessary if the Company is unable to continue as a going concern.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 16.2pt">&nbsp;</P>

<P STYLE="text-indent: 0.25in; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Because of the numerous risks and uncertainties
associated with our business, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve
or maintain profitability. Additionally, even if we are able to generate revenue from Proclarix, we may not become profitable. If we fail
to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at
planned levels and may be forced to reduce our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Recent Developments</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Resignation of Andrew Oakley and Thomas
Meier as Directors; Elections of Sammy Dorf as Chairman of the Board</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective on April 20, 2026,
Andrew Oakley and Thomas Meier notified the Board of their resignation from the Board. As a result of their resignation from the Board
and effective as of the date mentioned herein, Mr. Oakley has also resigned from his position as Chairman of the Board and his service
on the Audit Committee, Compensation Committee and the Nominating and Corporate Governance Committee, and Mr. Meier has also resigned
from his service on the Compensation Committee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective on April 23, 2026,
the Board has appointed Sammy Dorf, an existing member of the Board, as Chairman of the Board. In connection with Mr. Dorf&rsquo;s election
as Chairman, the Compensation Committee of the Board has agreed to compensate Mr. Dorf $20,000 per year, payable on a quarterly basis,
commencing on the date of his election.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Election of Josh Epstein</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective as of April 23,
2026, the Board elected Josh Epstein to serve as a member of the Board and a member of the Audit Committee, Compensation Committee and
as the chair of the Nominating and Corporate Governance Committee. Mr. Epstein, a Class II director, will serve for a term expiring at
the Company&rsquo;s 2026 annual meeting of stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-right: 0; margin-bottom: 0pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For his service on the Board,
Mr. Epstein will receive compensation consistent with that of other non-employee directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Reverse Stock Split</I></B><I><FONT STYLE="font-size: 10pt">&nbsp;</FONT></I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On March 25, 2026, the Company
effected a reverse stock split of all shares of its issued and outstanding Common Stock at a ratio of one-for-five (1:5). The Company
accounted for the reverse stock split on a retrospective basis pursuant to Accounting Standards Codification (&ldquo;ASC&rdquo;) 260,
<I>Earnings Per Share</I>. All issued and outstanding common stock, common stock warrants, and share-based awards&rsquo; exercise prices
and per share data have been adjusted in these condensed consolidated financial statements, on a retrospective basis, to reflect the reverse
stock split for all periods presented. The number of authorized shares and par value of the preferred stock and common stock were not
adjusted because of the reverse stock split.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Realbotix Corp. Share Exchange Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
February 11, 2026, we entered into a Share Exchange Agreement (the &ldquo;Share Exchange Agreement&rdquo;), by and among (i) Onconetix,
(ii) Realbotix Corp., a company existing under the laws of the Province of Ontario (&ldquo;Parent&rdquo;), (iii) Simulacra Corporation,
a Delaware corporation and a wholly-owned subsidiary of Parent (the &ldquo;Seller&rdquo;) and (iv) Realbotix, LLC, a Delaware limited
liability company and wholly owned subsidiary of the Seller (the &ldquo;Realbotix&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Pursuant
to the Share Exchange Agreement, subject to the terms and conditions set forth therein, the Seller agreed to contribute and transfer to
us, and we agreed to acquire and accept, all of the issued and outstanding equity interests of Realbotix (the &ldquo;Realbotix Interests&rdquo;)
in exchange for newly issued shares of Common Stock. (the &ldquo;Share Exchange&rdquo; and the other transactions contemplated by the
Share Exchange Agreement, the &ldquo;Realbotix Transactions&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Unless
otherwise defined herein, the capitalized terms used below are defined in the Share Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Consideration</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
full consideration for the contribution of the Realbotix Interests, we will issue shares of Common Stock to the Seller (the &ldquo;Exchange
Shares&rdquo;), such that, immediately following the Closing and after giving effect to such issuance, the Seller will own a percentage
of our fully diluted shares (the &ldquo;Fully Diluted Shares&rdquo;) that will be adjusted based on Net Cash (as defined below) as follows:
(i) if Net Cash is greater than or equal to $12.5 million, but less than $15.0 million, Seller will own 90% of the Fully Diluted Shares,
(ii) if Net Cash is greater than or equal to $15.0 million, but less than $18.0 million, Seller will own 85% of the Fully Diluted Shares,
(iii) if Net Cash is greater than or equal to $18.0 million, but less than $20.0 million, Seller will own 80% of the Fully Diluted Shares
and (iv) if Net Cash is greater than or equal to $20.0 million, Seller will own 75% of the Fully Diluted Shares. &ldquo;Net Cash&rdquo;
means the amount of cash and cash equivalents held by us upon the Closing, whether received by Realbotix or us in connection with the
Realbotix Transactions, net of D&amp;O tail insurance costs; change-of-control or other payments owed to our officers and director of
as a result of the Realbotix Transactions; all our indebtedness; certain of our liabilities and our transaction expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Conversion of Company
Convertible Securities</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Prior
to the consummation of the Share Exchange, the holders of Realbotix Convertible Securities will exercise their rights to receive Realbotix
Interests pursuant to the terms of such Realbotix Convertible Securities (as defined below) at the applicable conversion ratio as set
forth in the Realbotix Convertible Securities (the &ldquo;Realbotix Convertible Securities Conversion&rdquo;). Upon completion of the
Realbotix Convertible Securities Conversion and prior to Closing, all Realbotix Convertible Securities will be canceled or terminated,
as applicable, will no longer be outstanding and will cease to exist and no payment or distribution will be made with respect thereto.
Each holder of Realbotix Convertible Securities thereafter will cease to have any rights with respect to such securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Closing Conditions</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
consummation of the Share Exchange is subject to customary closing conditions, including (i) the accuracy of the representations and warranties
of the parties (subject to customary materiality qualifiers); (ii) compliance in all material respects by the parties with their respective
covenants and agreements under the Share Exchange Agreement; (iii) delivery of customary closing certificates and good standing certificates;
(iv) receipt by Board of a fairness opinion; (v) the absence of any law, order or injunction prohibiting the consummation of the Realbotix
Transactions and (vi) receipt of any required third-party and regulatory approvals and consents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
obligation of the Realbotix, Parent and Seller to complete the Closing is subject to the condition that, at Closing, we shall have an
aggregate of at least $12.5 million in Net Cash (the &ldquo;Net Cash Condition&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Additionally,
the obligation of Realbotix, Parent and us to complete the Closing are subject to the conditions that (i) we have entered into an agreement
with an investor, reasonably acceptable to us and Realbotix, providing for an equity line of credit pursuant to which such investor would
commit to purchase up to an aggregate of $125.0 million of Common Stock and (ii) the conversion of our Preferred Stock into Common Stock
and the termination of or certain amendments to of all Onconetix Options and Onconetix Warrants (the &ldquo;Convertible Securities Condition&rdquo;).&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Termination</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
addition to termination by mutual written agreement, for the other party&rsquo;s uncured breach or if a governmental order permanently
prohibits the Closing, the Share Exchange Agreement provides for termination:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">By either party if the Closing has not been consummated on or before November 30, 2026, provided the terminating party is not in breach in a manner that caused the failure to close by such date. The date is automatically extended to December 20, 2026 if all conditions to Closing other than the Net Cash Condition have been satisfied.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">By either party if our stockholder approval is not obtained at the stockholder meeting (including any adjournment or postponement thereof).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">By Realbotix if a Buyer Adverse Recommendation Change (as defined in the Share Exchange Agreement) occurs prior to receipt of Buyer stockholder approval.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">By us in connection with entering into a definitive agreement for a Buyer Superior Proposal (as define in the Share Exchange Agreement).</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">By us if the audited Realbotix financial statements have not been delivered by April 30, 2026.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 21.4pt; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Each
party will bear its own fees and expenses incurred in connection with the negotiation, execution and performance of the Share Exchange
Agreement and the Realbotix Transactions. However, the Share Exchange Agreement provides for the payment of termination fees and reimbursement
of transaction expenses in the following termination scenarios:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">In the event of a termination of the Share Exchange Agreement as a result of a material breach by either party, the breaching party will be required to pay a termination fee to the non-breaching party of $500,000 plus transaction expenses, with such transaction expenses not to exceed $500,000.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">In the event of a termination of the Share Exchange Agreement (i) by the Company as the result of a Buyer Adverse Recommendation Change or (ii) by Buyer upon entering into an agreement in respect of a Buyer Superior Proposal as a result of a Buyer Adverse Recommendation Change, Buyer must pay a termination fee of (A) $500,000 plus all Seller transaction expenses plus (B) if the transaction in respect of a Buyer Superior Proposal closes, an additional $1,500,000 upon closing of such transaction. If the transaction contemplated by the Buyer Superior Proposal doesn&rsquo;t close, Buyer is only obligated to pay $500,000 plus all Seller transaction expenses.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">In the event of a termination of the Share Exchange Agreement by Realbotix for failure to satisfy the Net Cash Condition, if Net Cash at the time of termination would be greater than $5.0 million (assuming the consummation of any Transaction Financing pursuant to Financing Agreements), we are obligated to pay Realbotix&rsquo;s transaction expenses, with such transaction expenses not to exceed $500,000.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Representations and
Warranties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">We,
Realbotix, and the Seller have made customary representations and warranties in the Share Exchange Agreement. The representations and
warranties of us, Realbotix, and the Seller will not survive the Closing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Covenants of the Parties</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Each
party to the Share Exchange Agreement agreed to use its commercially reasonable efforts to consummate the Realbotix Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
Share Exchange Agreement contains certain covenants by each of the parties, to be observed during the period between the execution of
the Share Exchange Agreement and Closing, including covenants regarding: (1) the provision of access to information, properties, books,
records and personnel; (2) delivery of audited financial statements of the Company; (3) litigation support; (4) the preparation and filing
of a registration statement, SEC reports and related disclosure documents and compliance with Nasdaq listing and reporting requirements;
(5) no insider trading; (6) further assurances; (7) public announcements; (8) confidentiality; (9) indemnification of directors and officers
and tail insurance; and (10) transfer taxes.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The
parties have agreed to take all necessary actions to cause our Board, immediately after closing, to consist of five directors, including:
(i) one person who is designated by us and reasonably acceptable to Realbotix and (ii) four persons who are designated by Realbotix and
reasonably acceptable to us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We
have also agreed to prepare and file with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) a registration statement on Form
S-4 in connection with the registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), of the issuance
of the Exchange Shares to be issued under the Share Exchange Agreement and containing a proxy statement (a &ldquo;Proxy Statement&rdquo;)
for the purpose of soliciting proxies from our stockholders for the matters to be acted on at the special meeting of our stockholders.
We have also agreed to use reasonable best efforts to maintain its listing on the Nasdaq and to enable the listing on Nasdaq of the Exchange
Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During
the time between the execution of the Share Exchange Agreement and the Closing, Realbotix agreed to conduct its business in the ordinary
course of business in all material respects and to comply with certain covenants regarding the operation of its business, including covenants
related to (i) amendments to the Realbotix&rsquo;s organizational documents; (ii) recapitalization of the Realbotix&rsquo;s equity interests;
(iii) issuance of additional securities; (iv) incurrence of additional indebtedness; (v) material changes to tax elections; (vi) amendments
to or termination of material contracts; (vii) maintenance of books and records; (viii) establishment of any subsidiary or entry into
a new line of business; (ix) maintenance of insurance policies; (x) revaluation of material assets or material changes in accounting methods,
principles or policies, except as required to comply with U.S. GAAP; (xi) waiver, settlement or compromise of material claims, actions
or proceedings, subject to specified thresholds; (xii) acquisition of equity interests or assets, or any other form of business combination,
outside of the ordinary course of business; (xiii) capital expenditures in excess of specified thresholds; (xiv) adoption of a plan of
liquidation, dissolution, merger, consolidation, restructuring, recapitalization or other reorganization; (xv) voluntary incurrence of
liabilities or obligations in excess of specified thresholds other than pursuant to contracts in existence as of the date of the Share
Exchange Agreement or entered into in the ordinary course of business; (xvi) sale, lease, license or other disposition of any material
portion of the Realbotix&rsquo;s assets, properties or rights; (xvii) entry into any agreement, understanding or arrangement relating
to the voting of the Realbotix&rsquo;s equity interests; (xviii) taking any action that would reasonably be expected to materially delay
or impair the obtaining of any required governmental or regulatory consents in connection with the Share Exchange Agreement; or (xix)
authorization or agreement to take any of the foregoing actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">During
the same period, we also agreed to conduct its business in the ordinary course of business in all material respects and to comply with
certain interim operating covenants, including covenants restricting our ability, without Realbotix&rsquo;s prior written consent (subject
to specified exceptions), to (i) amend its organizational documents; (ii) effect mergers, consolidations, acquisitions, liquidations,
restructurings or other business combinations; (iii) issue, repurchase, redeem or otherwise modify its equity securities or declare dividends
or other distributions; (iv) incur additional indebtedness or guarantee obligations of third parties; (v) dispose of material assets or
subsidiaries; (vi) make material loans, advances or capital contributions; (vii) make material tax elections or changes in accounting
methods, principles or practices, except as required by applicable law, GAAP or Regulation S-K; (viii) amend, terminate, waive or assign
material contracts other than in the ordinary course of business; (ix) fail to maintain books, records or insurance coverage in the ordinary
course of business; (x) establish subsidiaries or enter into new lines of business; (xi) settle material litigation or other proceedings
other than within specified thresholds; (xii) make capital expenditures or incur liabilities in excess of specified thresholds; (xiii)
enter into arrangements relating to the voting of Common Stock; (xiv) take actions that would reasonably be expected to materially delay
or impair the receipt of required governmental or regulatory approvals; or (xv) authorize, commit or publicly propose any of the foregoing
actions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>Governing Law </I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Share Exchange Agreement is governed by the
laws of the State of Delaware.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series E PIPE Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 1, 2025, the Company
entered into a securities purchase agreement (the &ldquo;Series E Securities Purchase Agreement&rdquo;) with institutional investor(s)
and sold to such institutional investors(s)(collectively, the &ldquo;Series E PIPE Investors&rdquo;), an aggregate of 7,813 shares of
Series E convertible preferred stock, par value $0.00001 per share (&ldquo;Series E Preferred Stock&rdquo;), which are convertible into
common stock of the Company, $0.00001 par value per share and warrants (the &ldquo;Series E Warrants&rdquo;) to purchase 405,045 shares
of Common Stock on a post-reverse split basis, for an aggregate purchase price of approximately $6.25 million, which was also equal to
the net cash proceeds. The exercise price of the Series E Warrants was $19.288 on a post-reverse split basis, and further reduced to $0.7298
per share as a result of anti-dilution contained in the Series E Warrant. The Series E Warrants are exercisable beginning on the issuance
date and expire on the third anniversary of the issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Concurrently with entering
into the Series E Securities Purchase Agreement, the Company also entered into a registration rights agreement with the Series E PIPE
Investors, pursuant to which it has agreed to provide the Series E PIPE Investors with certain registration rights related to the shares
of Common Stock underlying the shares of Series E Preferred Stock and Series E Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Series D PIPE Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On September 22, 2025, the
Company entered into a securities purchase agreement (the &ldquo;Series D Securities Purchase Agreement&rdquo;) with eleven institutional
investors, and sold or exchanged debt, to such investors (collectively, the &ldquo;Series D PIPE Investors&rdquo;) an aggregate of 16,099
shares of Series D convertible preferred stock, par value $0.00001 per share (&ldquo;Series D Preferred Stock&rdquo;), which includes
an issuance of 500 shares of Series D Preferred Stock to the lead investor in consideration for the Series D PIPE Investors&rsquo; irrevocable
commitment to purchase shares of the Series D Preferred Stock, and warrants (the &ldquo;Series D Warrants&rdquo;) to purchase 872,565
shares of Common Stock on a post-reverse split basis, for an aggregate purchase price of approximately $12.9 million and net cash proceeds
of $9.3 million. The exercise price of the Series D Warrants was $18.448 on a post-reverse split basis and further reduced to $0.7298
per share as a result of anti-dilution contained in the Series D Warrant. The Series D Warrants are exercisable beginning on the issuance
date and expire on the third anniversary of the issuance date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Concurrently with entering
into the Series D Securities Purchase Agreement, the Company also entered into a registration rights agreement with the Series D PIPE
Investors, pursuant to which it has agreed to provide the Series D PIPE Investors with certain registration rights related to the shares
of Common Stock underlying the shares of Series D Preferred Stock and Series D Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Amendment to Series D and Series E Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On December 23, 2025, the
Company entered into Limited Waiver Agreements (the &ldquo;Warrant Limited Waiver&rdquo;) with all holders of the Series D and Series
E Warrants, effective as of October 1, 2025, pursuant to which such holders agreed to waive certain provisions of their Series D Warrants
and Series E Warrants. Specifically, in the event the Company issues securities with a conversion price dependent on the price of the
Common Stock (the &ldquo;Variable Price&rdquo;), the holders of Series D Warrants and Series E Warrants will no longer have the optional
right to convert their applicable Series D Warrants and Series E Warrants at the Variable Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, the Warrant
Limited Waiver waived the right of the Series D Warrants and the Series E Warrants to receive a guaranteed cash payment in connection
with a &ldquo;Fundamental Transaction&rdquo; (as such term is defined in the Series D Warrants and Series E Warrants). Instead, in connection
with a &ldquo;Fundamental Transaction&rdquo; that is not within the Company&rsquo;s control, the holders of Series D Warrants and Series
E Warrants are entitled only to receive the same form and proportion of consideration (or deemed common stock of the successor entity,
if no such consideration is paid) as is offered and paid to holders of Common Stock, the definition of &ldquo;Fundamental Transaction&rdquo;
in Series D Warrants and the Series E Warrants was further amended by the Warrant Limited Waiver to replace each reference to &ldquo;at
least&rdquo; 50% with &ldquo;more than&rdquo; 50% of the outstanding Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><B><I>Termination of
Ocuvex Business Combination Agreement</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On
July 16, 2025, the Company entered into an Agreement and Plan of Merger with (i) Onconetix Merger Sub, Inc., a Delaware corporation and
a direct, wholly owned subsidiary of the Company, and (ii) Ocuvex Therapeutics, Inc., a Delaware corporation (&ldquo;Ocuvex&rdquo;, and
such agreement, the &ldquo;Ocuvex Merger Agreement&rdquo;). Pursuant to the Merger Agreement, Merger Sub will merge with and into Ocuvex,
with Ocuvex surviving the merger as a direct, wholly owned subsidiary of the Company (the &ldquo;Ocuvex Merger&rdquo; and the other transactions
contemplated by the Merger Agreement, the &ldquo;Ocuvex Transactions&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Effective
September 24, 2025, pursuant to Section 9.01(a) of the Merger Agreement, Ocuvex and the Company entered into a Termination and Release
Agreement (the &ldquo;Termination Agreement&rdquo;) pursuant to which they agreed to terminate the Ocuvex Merger Agreement and the transactions
contemplated thereby. The Termination Agreement also terminates and makes void the ancillary documents entered by and among Ocuvex and
the Company in connection with the Ocuvex Merger Agreement. The Termination Agreement also provides for a mutual release of claims among
the Parties and their affiliates and in consideration of the foregoing, the Company agreed to pay to Ocuvex, an amount equal to <B>$</B>302,343.55
(the &ldquo;Termination Payment&rdquo;), which represents all amounts payable by the Company to Ocuvex pursuant to Section 6.02(f) of
the Merger Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As
of September 24, 2025, Ocuvex confirmed receipt of the Termination Payment, and as a result the Ocuvex Merger Agreement is of no further
force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series C PIPE Financing</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 1, 2024, the Board
authorized the Company to create a series of 10,000 shares of preferred stock designated as &ldquo;Series C convertible Preferred Stock&rdquo;,
with a par value of $0.00001, pursuant to the certificate of designations. At any time after the initial issuance date of Series C convertible
Preferred Stock, each Series C Preferred Share shall be convertible into validly issued, fully paid and non-assessable shares of Common
Stock. The holders of Series C Preferred Stock are entitled to dividends, on an as-if converted basis, equal to and in the same form as
dividends actually paid on shares of Common Stock, when and if actually paid. In addition, from and after the occurrence and during the
continuance of any Triggering Event, dividends (&ldquo;Default Dividends&rdquo;) will accrue on the Stated Value of each Series C Preferred
Share at a rate of fifteen percent (15.0%) (the &ldquo;Default Rate&rdquo;) per annum. Each holder is entitled to convert any portion
of the outstanding Series C Preferred Shares held by such holder into validly issued, fully paid and non-assessable Conversion shares
at the Conversion Rate, which can be determined by dividing (x) the post-reverse split Conversion Amount of such Series C Preferred Share
by (y) the post-reverse split Conversion Price, $22.528, subject to adjustment as provided in the Series C Certificate of Designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On October 2, 2024, the Company
entered into, and sold, to six institutional investors (collectively, the &ldquo;PIPE Investors&rdquo;), pursuant to the securities purchase
agreement an aggregate of 3,499 shares of Series C Preferred Stock which includes an issuance of 840 shares of Series C Preferred Stock
to the lead investor in consideration for the PIPE Investors&rsquo; irrevocable commitment to purchase shares of the Series C Preferred
Stock, and warrants to purchase 1,392 shares of Common Stock on a post-reverse split basis for aggregate net cash proceeds to the Company
of $1.9 million. The exercise price of the warrants is $1,862.50 on a post-reverse split basis, and the warrants are exercisable six months
after the issuance date and expire on the third anniversary of the Initial Exercisability Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In no event may any Series
C Preferred Shares be converted (or Series C Warrants be exercised) and shares of Common Stock be issued to any holder if after giving
effect to the issuance of shares of Common Stock upon such conversion of the Series C Preferred Shares (or exercise of the Series C Warrants),
the holder (together with its affiliates, if any) would beneficially own more than 4.99% of the outstanding shares of Common Stock, which
we refer to herein as the &ldquo;Series C PIPE Blocker&rdquo;. The Series C PIPE Blocker may be raised or lowered to any percentage not
in excess of 9.99% at the option of the applicable holder of the Series C Preferred Shares (or Series C Warrants), except that any raise
will only be effective upon 61-days&rsquo; prior notice to the Company.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">On July 16, 2025, the Company
exercised its voluntary adjustment right under the Series C to lower the conversion price of the Series C Preferred Stock, until July
31, 2025, to a post-reverse split of $17.50, and holders of 2,130 shares Series C Preferred Stock agreed to convert their shares into
shares of Common Stock. As of September 30, 2025, 7 shares of Series C Preferred Stock were outstanding, after the exchange of 203 shares
of Series C Preferred Stock into 244 shares of Series D Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As of December 31, 2025,
7 shares of Series C Preferred Stock were outstanding from the original issuance of 3,499 shares of Series C Preferred Stock to institutional
investors, after the i) redemption of 1,369 shares of Series C Preferred Stock for aggregate consideration of $1.71 million, ii) the conversion
of 1,920 shares of Series C Preferred Stock into shares of Common Stock, and iii) the exchange of 203 shares of Series C Preferred Stock
into 244 shares of Series D Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

</DIV>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<DIV STYLE="padding-right: 4.5pt; padding-left: 4.5pt; border: Black 1.5pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>ABOUT THIS OFFERING</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%">Common Stock outstanding prior to this offering</TD>
    <TD STYLE="white-space: nowrap; width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 84%">11,464,572 shares</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Shares of Common Stock offered by the Selling Stockholder</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">Up to 25,000,000 shares of Common Stock (assuming the shares to be issued are sold at a price of approximately $0.6771 per share, which, in accordance with the terms of the ELOC Purchase Agreement, is equivalent to or greater than 90% of the daily volume weighted average price (the &ldquo;VWAP&rdquo;) of the Common Stock for the five trading days immediately preceding April 24, 2026)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Common Stock to be outstanding after this offering</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">36,464,572 shares (assuming the issuance of all shares of Common Stock issuable under the ELOC Purchase Agreement)</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Use of proceeds</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We are not selling any securities under this prospectus
    and will not receive any proceeds from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive
    up to $25.0 million in aggregate gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares
    of our Common Stock pursuant to the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone
    may be less than this amount depending on the number of shares of our Common Stock sold and the price at which the shares of our Common
    Stock are sold. Through April 24, 2026, the Company has sold approximately 701,933 split-adjusted shares under the ELOC Purchase Agreement
    for aggregate proceeds of approximately $8.1 million.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the ELOC Purchase Agreement, 30% of
    the gross proceeds to the Company from any sale of Common Stock thereunder must be applied towards the redemption of the Company&rsquo;s
    Series C Preferred Stock. As of the date of this prospectus, there are seven shares of Series C stock remain to be redeemed. Any remaining
    proceeds we receive from the sale of Common Stock under the ELOC Purchase Agreement will be used for general corporate and working capital
    or for other purposes that the Board, in its good faith, deems to be in the best interest of the Company</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Terms of this offering</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">The Selling Stockholder, including its transferees, donees, pledgees, assignees, and successors-in-interest, may sell, transfer, or otherwise dispose of any or all of the shares of Common Stock offered by this prospectus from time to time on The Nasdaq Capital Market or any other stock exchange, market or trading facility on which the shares are traded or in private transactions. The shares of Common Stock may be sold at fixed prices, at market prices prevailing at the time of sale, at prices related to prevailing market price or at negotiated prices.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Nasdaq symbol</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">Our Common Stock is listed on The Nasdaq Capital Market under the symbol &ldquo;ONCO.&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Risk Factors</TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD>
    <TD STYLE="text-align: justify">Investing in our securities involves significant risks. Before making a decision whether to invest in our securities, please read the information contained in or incorporated by reference under the heading &ldquo;<I>Risk Factors</I>&rdquo; in this prospectus, the documents we have incorporated by reference herein and under similar headings in other documents filed after the date hereof and incorporated by reference into this prospectus. See &ldquo;<I>Incorporation of Certain Information by Reference</I>&rdquo; and &ldquo;<I>Where You Can Find More Information</I>.&rdquo;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_003"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investing in our securities
involves a high degree of risk. You should carefully consider the risks and uncertainties described in this prospectus, in our most recent
Annual Report on Form 10-K, as supplemented and updated by subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K that
we have filed or will file with the SEC, and in other documents which are incorporated by reference into this prospectus, before making
an investment decision pursuant to this.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our business, financial condition
and results of operations could be materially and adversely affected by any or all of these risks or by additional risks and uncertainties
not presently known to us or that we currently deem immaterial that may adversely affect us in the future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to This Offering</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>It is not possible to predict the actual
number of shares of our Common Stock, if any, we will sell under the ELOC Purchase Agreement, or the actual gross proceeds resulting from
those sales or the dilution to you from those sales. Further, we may not have access to the full amount available under the ELOC Purchase
Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the ELOC Purchase
Agreement, Keystone shall purchase from us up to the lesser of $25.0 million in shares of our Common Stock and (ii) 19.99% of the total
number of shares of Common Stock outstanding immediately prior to the execution of the ELOC Purchase Agreement (the &ldquo;Exchange Cap&rdquo;),
upon the terms and subject to the conditions and limitations set forth in the ELOC Purchase Agreement (the &ldquo;Keystone Commitment
Amount&rdquo;); provided, however, that such limitations will not apply if we obtain stockholder approval to issue additional shares of
Common Stock. On October 11, 2024 the Company obtained stockholder approval to issue shares to Keystone in excess of the Exchange Cap.
Accordingly, we have reserved 25,000,000 shares for issuance under the ELOC Purchase Agreement and resale pursuant to this prospectus,
in addition to an aggregate of 1,152,352<B>&nbsp;</B>split-adjusted shares already reserved for issuance under the ELOC Purchase Agreement
and resale pursuant to a separate prospectus. The shares of our Common Stock that may be issued under the ELOC Purchase Agreement may
be sold by us to Keystone at our discretion from time to time from the Commencement Date (as defined below) until the earliest to occur
of (i) the 36-month anniversary of the effective date of the resale registration statement in connection with the ELOC Purchase Agreement
first declared effective by the SEC, or December 12, 2027, (ii) the date on which Keystone has purchased the Keystone Commitment Amount
pursuant to the ELOC Purchase Agreement, (iii) the date on which our Common Stock fails to be listed or quoted on Nasdaq or any successor
Eligible Market (as defined in the ELOC Purchase Agreement), and (iv) the date on which, pursuant to or within the meaning of any bankruptcy
law, a custodian is appointed for us or for all or substantially all of our property, or we make a general assignment for the benefit
of our creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We generally have the right
to control the timing and amount of any sales of our Common Stock to Keystone under the ELOC Purchase Agreement. Sales of our Common Stock,
if any, to Keystone under the ELOC Purchase Agreement will depend upon market conditions and other factors to be determined by us. We
may ultimately decide to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant
to the ELOC Purchase Agreement. Accordingly, we cannot guarantee that we will be able to sell all of the Keystone Commitment Amount or
how much in proceeds we may obtain under the ELOC Purchase Agreement. If we cannot sell securities under the Keystone Equity Financing,
we may be required to utilize more costly and time-consuming means of accessing the capital markets, which could have a material adverse
effect on our liquidity and cash position.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because the purchase price
per share of Common Stock to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the ELOC Purchase Agreement,
if any, will fluctuate based on the market prices of our Common Stock at the time we make such election, it is not possible for us to
predict, as of the date of this prospectus and prior to any such sales, the number of shares of Common Stock that we will sell to Keystone
under the ELOC Purchase Agreement, the purchase price per share that Keystone will pay for shares of Common Stock purchased from us under
the ELOC Purchase Agreement, or the aggregate gross proceeds that we will receive from those purchases by Keystone under the ELOC Purchase
Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are registering 25,000,000
shares of our Common Stock under this prospectus. As of April 24, 2026, there were 11,464,572 shares of Common Stock outstanding. If all
of the 25,000,000 shares of our Common Stock offered for resale by the Selling Stockholder under this prospectus were issued and outstanding
as of April 24, 2026, such shares would represent approximately 68.8% of the total number of shares of our Common Stock outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The actual number of shares
of our Common Stock Issuable will vary depending on the then current market price of shares of our Common Stock sold to the Selling Stockholder
in this offering and the number of shares of our Common Stock we ultimately elect to sell to the Selling Stockholder under the ELOC Purchase
Agreement. If it becomes necessary for us to issue and sell to Keystone under the ELOC Purchase Agreement more than the 25,000,000 shares
of our Common Stock (assuming the shares to be issued are sold at a price of approximately $0.6771 per share, which, in accordance with
the terms of the ELOC Purchase Agreement, is equivalent to or greater than 90% of the daily volume weighted average price (the &ldquo;VWAP&rdquo;)
of the Common Stock for the five trading days immediately preceding April 24, 2026) being registered for resale under this prospectus
in order to receive aggregate gross proceeds equal to $25.0 million under the ELOC Purchase Agreement, we must file with the SEC one or
more additional registration statements to register under the Securities Act the resale by Keystone of any such additional shares of our
Common Stock we wish to sell from time to time under the ELOC Purchase Agreement, which the SEC must declare effective, in each case before
we may elect to sell any additional shares of our Common Stock under the ELOC Purchase Agreement. Keystone is not obligated to buy any
Common Stock under the ELOC Purchase Agreement if such shares, when aggregated with all other Common Stock then beneficially owned by
Keystone and its affiliates (as calculated pursuant to Section 13(d) of the Securities Exchange Act, and Rule 13d-3 promulgated thereunder),
would result in Keystone beneficially owning Common Stock in excess of 4.99% of the then-outstanding shares of Common Stock. Our inability
to access a portion or the full amount available under the ELOC Purchase Agreement, in the absence of any other financing sources, could
have a material adverse effect on our business or results of operation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Keystone will pay less than the then-prevailing
market price for our Common Stock, which could cause the price of our Common Stock to decline.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The purchase price of our
Common Stock to be sold to Keystone under the ELOC Purchase Agreement is derived from the market price of our Common Stock on Nasdaq.
Shares to be sold to Keystone pursuant to the ELOC Purchase Agreement will be purchased at a discounted price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">For example, we may effect
sales to Keystone pursuant to a Fixed Purchase Notice (as defined below) at a purchase price equal to the lesser of 90% of (i) the daily
VWAP (as defined below) of the Common Stock for the five trading days immediately preceding the applicable Fixed Purchase Date (as defined
below) and (ii) the closing price of a share of Common Stock on the applicable Fixed Purchase Date during the full trading day on such
applicable Purchase Date. See &ldquo;<I>Keystone Committed Equity Financing</I>&rdquo; for more information.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">As a result of this pricing
structure, Keystone may sell the shares they receive immediately after receipt of such shares, which could cause the price of our Common
Stock to decrease.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;<B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I></I></B></P>

<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Investors who buy shares of Common Stock
from Keystone at different times will likely pay different prices.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the ELOC Purchase
Agreement, we have discretion, to vary the timing, price and number of shares of Common Stock we sell to Keystone. If and when we elect
to sell shares of Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has acquired such shares, Keystone
may resell all, some or none of such shares at any time or from time to time in its sole discretion and at different prices. As a result,
investors who purchase shares from Keystone in this offering at different times will likely pay different prices for those shares, and
so may experience different levels of dilution and in some cases substantial dilution and different outcomes in their investment results.
Investors may experience a decline in the value of the shares they purchase from Keystone in this offering as a result of future sales
made by us to Keystone at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell
a substantial number of shares to Keystone under the ELOC Purchase Agreement, or if investors expect that we will do so, the actual sales
of shares or the mere existence of our arrangements with Keystone may make it more difficult for us to sell equity or equity-related securities
in the future at a time and at a price that we might otherwise wish to effect such sales.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Future resales and/or issuances of
shares of Common Stock, including pursuant to this prospectus, or the perception that such sales may occur, may cause the market price
of our shares to drop significantly.</I></B><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The shares of our Common
Stock that may be issued under the ELOC Purchase Agreement may be sold by us to Keystone at our discretion from time to time from the
date of effectiveness of effectiveness of the registration statement of which this prospectus forms a part until the earliest to occur
of (i) the 36-month anniversary of the effective date of the registration statement of which this prospectus forms a part, (ii) the date
on which Keystone has purchased the Aggregate Limit pursuant to the ELOC Purchase Agreement, (iii) the date on which our Common Stock
fails to be listed or quoted on Nasdaq or any successor Eligible Market (as defined in the ELOC Purchase Agreement), and (iv) the date
on which, pursuant to or within the meaning of any bankruptcy law, a custodian is appointed for us or for all or substantially all of
our property, or we make a general assignment for the benefit of our creditors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The purchase price for shares
of our Common Stock that we may sell to Keystone under the ELOC Purchase Agreement will fluctuate based on the trading price of shares
of our Common Stock. Depending on market liquidity at the time, sales of shares of our Common Stock may cause the trading price of shares
of our Common Stock to decrease. We generally have the right to control the timing and amount of any future sales of shares of our Common
Stock to Keystone. Additional sales of shares of our Common Stock, if any, to Keystone will depend upon market conditions and other factors
to be determined by us. We may ultimately decide to sell to Keystone all, some or none of the additional shares of our Common Stock that
may be available for us to sell pursuant to the ELOC Purchase Agreement. If and when we do sell shares of our Common Stock to Keystone,
after Keystone has acquired shares of our Common Stock, Keystone may resell all, some or none of such shares of our Common Stock at any
time or from time to time in its discretion and at different prices. Therefore, sales to Keystone by us could result in substantial dilution
to the interests of other holders of shares of our Common Stock. In addition, if we sell a substantial number of shares of our Common
Stock to Keystone under the ELOC Purchase Agreement, or if investors expect that we will do so, the shares held by Keystone will represent
a significant portion of our public float and may result in substantial decreases to the price of our Common Stock. The actual sales
of shares of our Common Stock or the mere existence of our arrangement with Keystone may also make it more difficult for us to sell equity
or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The market price of shares
of our Common Stock could drop significantly if Keystone sells shares of Common Stock or is perceived by the market as intending to sell
them. These factors could also make it more difficult for us to raise additional funds through future offerings of shares of our Common
Stock or other securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may use proceeds from sales of our Common
Stock made pursuant to the ELOC Purchase Agreement in ways with which you may not agree or in ways which may not yield a significant return.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will have broad discretion
over the use of proceeds from sales of our Common Stock made pursuant to the ELOC Purchase Agreement, including for any of the purposes
described in the section entitled &ldquo;<I>Use of Proceeds</I>,&rdquo; and you will not have the opportunity, as part of your investment
decision, to assess whether the proceeds are being used appropriately. Because of the number and variability of factors that will determine
our use of the net proceeds, their ultimate use may vary substantially from their currently intended use. While we expect to use the net
proceeds from this offering as set forth in &ldquo;<I>Use of Proceeds</I>,&rdquo; we are not obligated to do so. The failure by us to
apply these funds effectively could harm our business, and the net proceeds may be used for corporate purposes that do not increase our
operating results or enhance the value of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Other Risks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Risks Related to our Financial Position and
Need for Capital</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We have incurred significant net losses
since inception, have only generated minimal revenue, and anticipate that we will continue to incur substantial net losses for the foreseeable
future and may never achieve profitability. Our stock is a highly speculative investment.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are a commercial-stage
biotechnology company that was incorporated in October 2018. Our net loss was $14.0 million and $58.7 million for the years ended December
31, 2025 and 2024, respectively. As of December 31, 2025, we had an accumulated deficit of $131.2 million. We also generated negative
operating cash flows of $9.7 million for the year ended December 31, 2025.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to continue to spend
significant resources to commercialize our product. We expect to incur substantial and increasing operating losses over the next several
years. As a result, our accumulated deficit will also increase significantly. Additionally, there can be no assurance that our current
product or those that may be under development by us in the future will be commercially viable. If we are unable to achieve profitability
or raise sufficient working capital, we may be unable to continue our operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>There is substantial doubt about our ability
to continue as a &ldquo;going concern,&rdquo; and we will require substantial additional funding to finance our long-term operations.
If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate our product or other operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have incurred substantial
operating losses since inception and expects to continue to incur significant operating losses for the foreseeable future. As of December
31, 2025, we had cash of approximately $5.2 million, a working capital deficit of approximately $3.1 million and an accumulated deficit
of approximately $131.2 million. In addition, as of April 24, 2026, our cash balance was approximately $4.2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We estimate, as of the date
of this prospectus, that our current cash balance is not sufficient to fund operations for one year from the date of issuance of these
consolidated financial statements. We believe that we will need to raise substantial additional capital to fund our continuing operations,
satisfy existing and future obligations and liabilities, and otherwise support the our working capital needs and business activities,
including the commercialization of Proclarix, which is still subject to further successful development and commercialization activities
within certain jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have entered into Series
D and Series E PIPE financings with certain investors in September 2025 and October 2025, respectively which provided us additional cash
flow to support our near-term operations. While such capital raises may enable us to sustain current operations and meet existing obligations,
we continue to generate recurring net operating losses and have not yet established sustained positive cash flows to support our strategic
growth initiatives. Such initiatives include the commercialization of Proclarix and our development and commercialization of future product
candidates. These factors raise substantial doubt on our ability to continue as a going concern for one year from the date of issuance
of our consolidated financial statements for the financial year ended December 31, 2025. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our
management plans for funding our operations include generating product revenue from sales of Proclarix, which is currently subject to
further successful development and commercialization activities within certain jurisdictions. Our management also intends to pursue additional
equity or debt financing to support operations and strategic initiatives. However, other than the outstanding Committed Equity Facility,
there are currently no committed sources of financing, and there is no assurance that additional funding will be available on favorable
terms, if at all. This uncertainty raises significant concern about our ability to sustain operations and execute our strategic initiatives.
If additional capital is not secured, we may need to curtail clinical trials, development, and commercialization efforts, and take further
measures to reduce expenses to conserve cash.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our future capital requirements
will depend on many factors, including:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the costs of future development and commercialization activities,
including product manufacturing, marketing, sales, royalties and distribution, for Proclarix, and other products for which we have received
or will receive marketing approval;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">our ability to maintain existing, and establish new, strategic
collaborations, licensing or other arrangements and the financial terms of any such agreements, including the timing and amount of any
future milestone, royalty, or other payments due under any such agreement;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">any product liability or other lawsuits related to our product;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the expenses needed to attract, hire, and retain skilled personnel;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the revenue, if any, received from commercial sales of Proclarix
or other products for which we may receive marketing approval;</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the costs to establish, maintain, expand, enforce, and defend
the scope of our intellectual property portfolio, including the amount and timing of any payments we may be required to make, or that
we may receive, in connection with licensing, preparing, filing, prosecuting, defending, and enforcing our patents or other intellectual
property rights; and</TD>
</TR></TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">&#9679;</TD><TD STYLE="text-align: justify">the costs of operating as a public company.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 22.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to raise additional
funds will depend on financial, economic, and other factors, many of which are beyond our control. We cannot be certain that additional
funding will be available on acceptable terms, or at all. We have no committed source of additional capital and if we are unable to raise
additional capital in sufficient amounts or on terms acceptable to us, we may be forced to delay, reduce or terminate our business activities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We are dependent on third parties, including
Labcorp, to develop, market, distribute and sell our products.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to receive revenues
is dependent upon the sales and marketing efforts of co-marketing partners and third-party distributors. In particular, the development
and commercialization of Proclarix in the United States is being pursued by Labcorp, pursuant to an exclusive license agreement that grants
Labcorp the exclusive right to develop and commercialize Proclarix, and other products developed by Labcorp using Proteomedix&rsquo;s
intellectual property covered by the license, in the United States for identification, screening, staging, predisposition, diagnosis,
prognosis, monitoring, prevention or treatment selection with respect to prostate cancer. However, we do not have control over Labcorp&rsquo;s
development and commercialization of Proclarix, and there can be no guarantee that Labcorp will continue to advance development and commercialization
efforts, or that Labcorp will successfully commercialize Proclarix in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Labcorp may terminate or
seek to renegotiate the terms of this agreement, which could adversely affect our business operations and financial condition. If Labcorp
terminates the agreement or demands terms that are less favorable to us, we may experience disruptions in our product development and
commercialization efforts, potentially leading to a loss of revenue and market share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if Labcorp
is unable to commercialize Proclarix in the United States, and we fail to reach an agreement with any other commercialization partner,
or upon reaching such an agreement that partner fails to sell a large volume of our products, it may have a negative impact on our business,
financial condition, and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Risks Related to Pending Share Exchange</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>We could fail to complete the Realbotix Transactions, or the
Realbotix Transactions may be completed on different terms.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There can be no assurance
that the Realbotix Transactions will be completed, or if completed, that they will be completed on the same or similar terms to those
set out in our previous disclosure. The Realbotix Transactions are subject to the satisfaction of a number of conditions precedent, some
of which are outside our control, which include, among others, performance by Simulacra and Realbotix of their respective obligations
and covenants in the Share Exchange Agreement. If these conditions are not satisfied (or waived) or the Realbotix Transactions are not
completed for any other reason, our stockholders will not receive the consideration contemplated in the Share Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Realbotix Transactions
are not completed, our ongoing business may be adversely affected as a result of the costs (including opportunity costs) incurred in respect
of pursuing the Realbotix Transactions, and we could experience negative reactions from the financial markets, which could cause a decrease
in the market price of our Common Stock, particularly if the current market price reflects market assumptions that the Realbotix Transactions
will be completed or completed on certain terms. We may also experience negative reactions from our employees and there could be negative
impact our ability to attract future business opportunities. Failure to complete the Realbotix Transactions or a change in the terms of
the Realbotix Transactions could each have a material adverse effect on our business, financial condition and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may pay a transaction fee to Realbotix
if we fail to complete the Realbotix Transactions and could significantly harm the market price of our common stock and negatively affect
our future business and operations.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If the Realbotix Transactions
is not completed and the Share Exchange Agreement is terminated under certain circumstances, we may be required to pay Realbotix a termination
fee as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">In the event of a termination of the Share Exchange Agreement as a result of a material breach by either party, the breaching party will be required to pay a termination fee to the non-breaching party of $500,000 plus transaction expenses, with such transaction expenses not to exceed $500,000.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">In the event of a termination of the Share Exchange Agreement if (i) our Board deems a third-party offer to acquire our assets to be superior than the Share Exchange Agreement and is therefore in the best interest of our stockholders (the &ldquo;Buyer Superior Proposal&rdquo;) and/or (ii) enters into an agreement with a third-party to effectuate a Buyer Superior Proposal, we must pay a termination fee of (A) $500,000 plus all Realbotix transaction expenses plus (B) if the transaction in respect of a Buyer Superior Proposal closes, an additional $1,500,000 upon closing of such transaction. If the transaction contemplated by the Buyer Superior Proposal does not close, we are only obligated to pay $500,000 plus all Realbotix transaction expenses.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="text-align: justify; width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">In the event of a termination of the Share Exchange Agreement by Realbotix for failure to satisfy the Net Cash Condition (as defined in the Share Exchange Agreement), if Net Cash (as defined in the Share Exchange Agreement) at the time of termination would be greater than $5.0 million (assuming the consummation of any transactions for financing), we are obligated to pay Realbotix&rsquo;s transaction expenses, with such transaction expenses not to exceed $500,000.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Even if a termination fee
is not payable in connection with a termination of the Share Exchange Agreement, we will have incurred significant fees and expenses,
which must be paid whether or not the Realbotix Transactions is completed. Further, if the Realbotix Transactions is not completed, it
could significantly harm the market price of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, if the Share
Exchange Agreement is terminated and we determine to seek another business combination, there can be no assurance that we will be able
to find a partner and close an alternative transaction on terms that are as favorable as or more favorable to us than the terms set forth
in the Share Exchange Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The closing of the Realbotix Transactions
is subject to approval by our stockholders. Failure to obtain these other required approvals would prevent the closing of the Realbotix
Transactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The closing of the Realbotix
Transactions is subject to certain approvals by our stockholders. Failure to obtain the required stockholder approvals may result in a
material delay in, or the abandonment of, the Realbotix Transactions. Any delay in completing the Realbotix Transactions may materially
adversely affect the timing and benefits that are expected to be achieved from the Realbotix Transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>If the Realbotix Transactions is not completed,
the Board may decide to pursue our dissolution and liquidation. In such an event, the amount of cash available for distribution to our
stockholders will depend heavily on the timing of such liquidation as well as the amount of cash that will need to be reserved for commitments
and contingent liabilities.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">There can be no assurance
that the Realbotix Transactions will be completed. If the Realbotix Transactions is not completed, our Board may decide to pursue our
dissolution and liquidation. In such an event, the amount of cash available for distribution to our stockholders will depend heavily on
the timing of such decision, as with the passage of time the amount of&nbsp;cash available for distribution will be reduced we continue
to fund our operations. In addition, if our Board were to approve and recommend, and our stockholders were to approve, our dissolution
and liquidation, we would be required under Delaware corporate law to pay its outstanding obligations, as well as to make reasonable provision
for contingent and unknown obligations, prior to making any distributions in liquidation to our stockholders. As a result of this requirement,
a portion of our remaining cash assets may need to be reserved pending the resolution of such obligations. In addition, we may be subject
to litigation or other claims related to a dissolution and liquidation. If a dissolution and liquidation were pursued, our Board, in consultation
with its advisors, would need to evaluate these matters and make a determination about a reasonable amount to reserve. Accordingly, holders
of our common stock could lose all or a significant portion of their investment in the event of pir liquidation, dissolution or winding
up.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The issuance of securities would result
in significant dilution in the equity interest of existing stockholders and adversely affect the marketplace of our Common Stock.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The issuance or conversion
of Common Stock or other securities convertible into Realbotix Common Stock in connection with the Realbotix Transactions would result
in significant dilution in the equity interest of our existing stockholders and adversely affect the market price of our Common Stock.
In addition, future issuances of, or conversions of, securities may result in significant dilution to our existing stockholders, which
could adversely impact your investment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Our stockholders may not realize a benefit
from the acquisition of Realbotix commensurate with the ownership dilution they will experience in connection with the Realbotix Transactions
contemplated by the Share Exchange Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">If we are unable to realize
the full strategic and financial benefits currently anticipated from the Realbotix Transactions, our stockholders may experience a dilution
of their ownership interests without receiving any commensurate benefit, or only receiving part of the commensurate benefit to the extent
we are able to realize only part of the strategic and financial benefits currently anticipated from the Realbotix Transactions. The Realbotix
Transactions may pose integration challenges which could result in management and business disruptions, any of which could harm our results
of operation, business prospects, and impair the value of the Realbotix Transactions to our stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The failure to successfully integrate the
businesses of us and Realbotix in the expected timeframe would adversely affect our future results.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our ability to successfully
integrate our operations and those of Realbotix will depend, in part, on our ability to realize the anticipated benefits from the Realbotix
Transactions. If we are not able to achieve the stated objectives, the anticipated benefits of the Realbotix Transactions may not be realized
fully, or at all, or may take longer to realize than expected, and the value of our Common Stock may be adversely affected. In addition,
the integration of our and Realbotix&rsquo;s respective businesses will be a time-consuming and expensive process. Proper planning and
effective and timely implementation will be critical to avoid any significant disruption to our operations. It is possible that the integration
process could result in the loss of key employees, the disruption of our business or the identification of inconsistencies in standards,
controls, procedures and policies that adversely affect our ability to maintain relationships with customers, suppliers, distributors,
creditors or lessors, or to achieve the anticipated benefits of the Realbotix Transactions. Delays encountered in the integration process
could have a material adverse effect on our operating results and financial condition, including the value of our Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The pending Realbotix Transactions may divert
the attention of our management.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The pending Realbotix Transactions
could cause the attention of our management to be diverted from the day-to-day operations. These disruptions could be exacerbated by a
delay in the completion of the Realbotix Transactions and could have an adverse effect on our business, operating results or prospects
regardless of whether the Realbotix Transactions are ultimately completed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Unexpected market disruptions may cause
major losses for us not anticipated under the Share Exchange Agreement.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We may incur major losses
in the event of disrupted markets and other extraordinary events in which market behavior diverges significantly from historically recognized
patterns, which may offset any potential benefits achieved under the Share Exchange Agreement. The risk of loss in such events may be
compounded by the fact that, in disrupted markets, many positions become illiquid, making it difficult or impossible to close out positions
against which markets are moving. Market disruptions caused by unexpected political, military and terrorist events, or other factors,
may from time to time cause dramatic losses for us.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Risks associated with changes in the technology
industry.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Realbotix operates in a competitive
industry characterized by rapid technological change and evolving industry standards. Realbotix&rsquo;s ability to attract new customers
to its business, and generate revenue from existing customers will depend largely on its ability to anticipate industry standards and
trends, respond to technological advances in its industry, and keep pace with technological developments and customers&rsquo; increasingly
sophisticated needs. The success of any enhancement of Realbotix&rsquo;s products or new related applications will depend on several factors,
including the timely completion and market acceptance of the products.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Realbotix&rsquo;s services are expected to embody
complex technology that may not meet those standards, changes and preferences. Realbotix&rsquo;s ability to design, develop and commercially
launch products depends on a number of factors, including, but not limited to, its ability to design and implement solutions and services
at an acceptable cost and quality, its ability to attract and retain skilled technical employees, the availability of critical components
from third parties, and its ability to successfully complete the development of the products in a timely manner. There is no guarantee
that Realbotix will be able to respond to market demands. If Realbotix is unable to effectively respond to technological changes or fails
or delays to develop services in a timely and cost-effective manner, Realbotix may be unable to recover our development expenses which
could negatively impact sales, profitability and the continued viability of its business.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We may be unable to protect Realbotix&rsquo;s
intellectual property.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Realbotix&rsquo;s commercial
success depends to a significant degree upon its ability to develop new or improved technologies, instruments, and services, and to obtain
patents, where appropriate, or other intellectual property rights or statutory protection for these technologies and products in Canada
and the United States. Despite devoting resources to the research and development of proprietary technology, Realbotix, may not be able
to develop new technology that is patentable or protectable. Further, patents issued to Realbotix, if any, could be challenged, held invalid
or unenforceable, or be circumvented and may not provide Realbotix with necessary or sufficient protection or a competitive advantage.
Competitors and other third parties may be able to design around Realbotix&rsquo;s intellectual property or develop technology similar
to Realbotix&rsquo;s products that is not within the scope of such intellectual property. Realbotix&rsquo;s inability to secure its indirectly
owned, intellectual property rights may have a materially adverse effect on its business and results of operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>The business of Realbotix is exposed to
cybersecurity risks.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Cyber incidents can result
from deliberate attacks or unintentional events, and may arise from internal sources (e.g., employees, contractors, suppliers and operational
risks) or external sources (e.g., nation states, terrorists, hacktivists, competitors and acts of nature). Cyber incidents include unauthorized
access to information systems and data (e.g., through hacking or malicious software) for purposes of misappropriating or corrupting data
or causing operational disruption. Cyber incidents also may be caused in a manner that does not require unauthorized access, such as causing
denial-of-service attacks on websites (e.g., efforts to make network services unavailable to intended users). A cyber incident that affects
Realbotix might cause disruptions and adversely affect their respective business operations and might also result in violations of applicable
law (e.g., personal information protection laws), each of which might result in potentially significant financial losses and liabilities,
regulatory fines and penalties, reputational harm, and reimbursement and other compensation costs to Realbotix. In addition, substantial
costs might be incurred to investigate, remediate, and prevent cyber incidents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>We expect to incur significant transaction
costs in connection with the Realbotix Transactions.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We expect to incur a number
of non-recurring costs associated with negotiating and completing the Realbotix Transaction. These fees and costs have been, and will
continue to be, substantial and, in many cases, will be borne by us whether or not the Realbotix Transaction is completed. A substantial
majority of our non-recurring expenses will consist of transaction costs related to the Realbotix Transactions and include, among others,
fees paid to financial, legal, accounting and other advisors. We will continue to assess the magnitude of theses costs, and we may incur
additional unanticipated costs. The costs described above and any unanticipated costs and expenses, many of which will be borne by us
even if the Realbotix Transaction is not completed, could have an adverse effect on our financial condition and operating results.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B><A NAME="a_004"></A>ELOC
Financing</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">On
October 2, 2024, the Company entered into a Common Stock ELOC Purchase Agreement relating to a Committed Equity Facility with Keystone,
whereby the Company may offer and sell, from time to time at its sole discretion, and whereby Keystone has committed to purchase, up to
$25.0 million of the Company&rsquo;s newly issued Common Stock, subject to the limitations described below. Concurrently with entering
into the ELOC Purchase Agreement, the Company also entered into a registration rights agreement with Keystone, pursuant to which it agreed
to provide Keystone with certain registration rights related to the shares issued under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Company may, from time to time and at its sole discretion, direct Keystone to purchase shares of Common Stock upon the satisfaction of
certain conditions set forth in the Common Stock Purchase Agreement at a purchase price per share based on the market price of Common
Stock at the time of sale as computed under the ELOC Purchase Agreement. There is no upper limit on the price per share that Keystone
could be obligated to pay for Common Stock under the ELOC Purchase Agreement. The Company will control the timing and amount of any sales
of Common Stock to Keystone, and Keystone has no right to require the Company to sell any shares to it under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Company does not have a right to commence any sales of Common Stock to the Purchaser under the ELOC Purchase Agreement until the time
when all of the conditions to the Company&rsquo;s right to commence sales of Common Stock to the Purchaser set forth in the ELOC Purchase
Agreement have been satisfied, including that a registration statement covering the resale of such shares is declared effective by the
SEC and the final form of prospectus is filed with the SEC (the &ldquo;Commencement Date&rdquo;). Over the 36-month period from and after
the Commencement Date, the Company will control the timing and amount of any sales of Common Stock to the Purchaser. Actual sales of shares
of Common Stock to the Purchaser under the ELOC Purchase Agreement will depend on a variety of factors to be determined by the Company
from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by us as to the
appropriate sources of funding and the Company&rsquo;s operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although the Purchase Agreement
provides that we may sell up to an aggregate of $25.0 million of our shares of our Common Stock to Keystone, only 25,000,000 shares of
our Common Stock (assuming the shares are sold at a price of $0.6771 per share) are being registered for resale under the registration
statement that includes this prospectus, in addition to 701,933<B>&nbsp;</B>split-adjusted shares already issued and sold under the ELOC
Purchase Agreement and resale pursuant to separate prospectuses. If it becomes necessary for us to issue and sell to Keystone under the
Purchase Agreement more shares than are being registered for resale under this prospectus in order to receive aggregate gross proceeds
equal to $25.0 million under the Purchase Agreement, we must first file with the SEC one or more additional registration statements to
register under the Securities Act the resale by Keystone of any such additional shares of our Common Stock we wish to sell from time to
time under the Purchase Agreement, which the SEC must declare effective, in each case, before we may elect to sell any additional shares
of our Common Stock to Keystone under the Purchase Agreement. Through April 24, 2026, the Company has sold approximately 701,933 split-adjusted
shares under the ELOC Purchase Agreement for aggregate proceeds of approximately $8.1 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
no event will the Company issue to the Purchaser under the ELOC Purchase Agreement more than 19.99% of the total number of shares of Common
Stock outstanding immediately prior to the execution of the Common Stock Purchase Agreement, unless (i) the Company obtains the approval
of the issuance of such shares by its stockholders in accordance with the applicable stock exchange rules or (ii) sales of Common Stock
are made at a price equal to or in excess of the lower of (A) the closing price immediately preceding the delivery of the applicable notice
to the Purchaser and (B) the average of the closing prices of the Common Stock for the five business days immediately preceding the delivery
of such notice, such that the sales of such Common Stock to the Purchaser would not count toward the Exchange Cap because they are &ldquo;at
market&rdquo; under applicable stock exchange rules. On October 11, 2024 the Company obtained stockholder approval to issue shares to
Keystone in excess of the Exchange Cap.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
all cases, the Company may not issue or sell any shares of Common Stock to Keystone under the Common Stock Purchase Agreement which, when
aggregated with all other shares of Common Stock then beneficially owned by Keystone and its affiliates (as calculated pursuant to Section
13(d) of the Securities Exchange Act of 1934, as amended, and Rule 13d-3 promulgated thereunder), would result in Keystone beneficially
owning more than 4.99% of the outstanding shares of Common Stock (the &ldquo;ELOC Blocker&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">At
any time from and after the Commencement Date, on any business day on which the closing sale price of the Common Stock is equal to or
greater than $0.05 (the &ldquo;Purchase Date&rdquo;), the Company may direct the Purchaser to purchase a specified number of shares of
Common Stock (a &ldquo;Fixed Purchase&rdquo;) not to exceed 100,000 shares at a purchase price equal to the lesser of 90% of (i) the daily
volume weighted average price (the &ldquo;VWAP&rdquo;) of the Common Stock for the five trading days immediately preceding the applicable
Purchase Date for such Fixed Purchase and (ii) the lowest sale price of a share of Common Stock on the applicable Purchase Date for such
Fixed Purchase during the full trading day on such applicable Purchase Date. In any case, the Purchaser&rsquo;s commitment in any single
Fixed Purchase may not exceed $10,000.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">In
addition, at any time from and after the Commencement Date, on any business day on which the closing sale price of the Common Stock is
equal to or greater than $0.05 and such business day is also the Purchase Date for a Fixed Purchase of an amount of shares of Common Stock
not less than the applicable Fixed Purchase Maximum Amount (as defined in the Common Stock Purchase Agreement) (the &ldquo;VWAP Purchase
Date&rdquo;), the Company may also direct the Purchaser to purchase, on the immediately following business day, an additional number of
shares of Common Stock in an amount up to the Maximum VWAP Purchase Amount (as defined in the Common Stock Purchase Agreement) (a &ldquo;VWAP
Purchase&rdquo;) at a purchase price equal to the lesser of 90% of (i) the closing sale price of the Common Stock on the applicable VWAP
Purchase Date and (ii) the VWAP during the period on the applicable VWAP Purchase Date beginning at the opening of trading and ending
at the VWAP Purchase Termination Time (as defined in the Purchase Agreement). At any time from and after the Commencement Date, on any
business day that is also the VWAP Purchase Date for a VWAP Purchase, the Company may also direct the Purchaser to purchase, on such same
business day, an additional number of shares of Common Stock in an amount up to the Maximum Additional VWAP Purchase Amount (as defined
in the ELOC Purchase Agreement) (an &ldquo;Additional VWAP Purchase&rdquo;) at a purchase price equal to the lesser of 90% of (i) the
closing sale price of the Common Stock on the applicable Additional VWAP Purchase Date and (ii) the VWAP during the Additional VWAP Purchase
Period (as defined in the Common Stock Purchase Agreement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
net proceeds under the Purchase Agreement to the Company will depend on the frequency and prices at which the Company sells shares of
its Common Stock to Keystone. Pursuant to the ELOC Purchase Agreement, up to 30% of the proceeds from each Fixed Purchase and VWAP Purchase
Notice must be used to redeem shares of Series C Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
ELOC Purchase Agreement contains customary representations, warranties and agreements of the Company and Keystone, limitations and conditions
regarding sales of Common Stock, indemnification rights and other obligations of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">There
are no restrictions on future financings, rights of first refusal, participation rights, penalties or liquidated damages in the ELOC Purchase
Agreement other than a prohibition (with certain limited exceptions) on entering into a dilutive securities transaction during certain
periods when the Company is selling Common Stock to Keystone under the Purchase Agreement. Keystone has agreed that, during the term of
the Purchase Agreement, it will not engage in or effect, directly or indirectly, any short sales involving the Company&rsquo;s securities
or any hedging transaction that transfers the economic risk of ownership of the Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">The
Purchase Agreement will automatically terminate on the earliest to occur of (i) the 36-month anniversary of the effective date of the
resale registration statement in connection with the ELOC Purchase Agreement first declared effective by the SEC, or December 12, 2027,
(ii) the date on which Keystone will have purchased from the Company under the ELOC Purchase Agreement an aggregate limit of shares of
Common Stock as defined therein, (iii) the date on which the Common Stock will have failed to be listed or quoted on Nasdaq or another
U.S. national securities exchange identified as an &ldquo;eligible market&rdquo; in the ELOC Purchase Agreement, (iv) the 30th trading
day after the date on which a voluntary or involuntary bankruptcy proceeding involving the Company has been commenced that is not discharged
or dismissed prior to such trading day, and (v) the date on which a bankruptcy custodian is appointed for all or substantially all of
the Company&rsquo;s property or the Company makes a general assignment for the benefit of creditors. The Company has the right to terminate
the ELOC Purchase Agreement at any time after the Commencement Date (as defined in the ELOC Purchase Agreement), at no cost or penalty,
upon one trading day&rsquo;s prior written notice to Keystone. Keystone has the right to terminate the Purchase Agreement upon ten trading
days&rsquo; prior written notice to the Company if certain specified events occur. The Company and Keystone may also agree to terminate
the ELOC Purchase Agreement by mutual written consent. Neither the Company nor Keystone may assign or transfer the Company&rsquo;s respective
rights and obligations under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">Concurrent
with the execution of the ELOC Purchase Agreement, the Company entered into a registration rights agreement with Keystone (the &ldquo;ELOC
Registration Rights Agreement&rdquo;), pursuant to which the Company agreed to file a registration statement covering the issuance and
sale of the maximum number of shares issuable under the ELOC Purchase Agreement as may be permitted under applicable rules. The Company
agreed to use its commercially reasonable efforts to cause the registration statement to be filed within 45 days after the closing of
the ELOC Purchase Agreement and to have such registration statement effective within 120 days of such closing (or 90 days of such closing
if the Company is notified by the Securities and Exchange Commission that such registration statement will not be reviewed or subject
to further review).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Effect of Sales of our Common Stock under the ELOC Purchase Agreements
on our Stockholders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Common Stock being registered
for resale in this offering may be issued and sold by us to the Selling Stockholder from time to time at our discretion, during the terms
described above. The resale by the Selling Stockholder of a significant quantity of shares registered for resale in this offering at any
given time, or the perception that these sales may occur, could cause the market price of our Common Stock to decline and to be highly
volatile. Sales of our Common Stock, if any, to Keystone under the ELOC Purchase Agreement will be determined by us in our sole discretion,
subject to the satisfaction of certain conditions in the ELOC Purchase Agreement and will depend upon market conditions and other factors.
We may ultimately decide to sell to Keystone all, some or none of the Common Stock that may be available for us to sell to Keystone pursuant
to the ELOC Purchase Agreement. If we elect to sell Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has
acquired such shares, Keystone may resell all, some or none of such Common Stock at any time or from time to time in its discretion and
at different prices. As a result, investors who purchase Common Stock from Keystone in this offering at different times will likely pay
different prices for those shares of Common Stock, and so may experience different levels of dilution and in some cases substantial dilution
and different outcomes in their investment results. See &ldquo;<I>Risk Factors</I>&mdash;<I>Risks Related to the Committed Equity Financings</I>&mdash;<I>Investors
who buy shares of Common Stock from Keystone at different times will likely pay different prices</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Investors may experience
a decline in the value of the Common Stock they purchase from Keystone in this offering as a result of future sales made by us to Keystone
at prices lower than the prices such investors paid for their shares in this offering. In addition, if we sell a substantial number of
shares of Common Stock to Keystone under the Keystone ELOC Purchase Agreement, or if investors expect that we will do so, the actual sales
of Common Stock or the mere existence of our arrangement with Keystone may make it more difficult for us to sell equity or equity-related
securities in the future at a time and at a price that we might otherwise wish to effect such sales.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Because the purchase price
per share to be paid by Keystone for the Common Stock that we may elect to sell to Keystone under the ELOC Purchase Agreement, if any,
will fluctuate based on the market prices of our Common Stock at the time we make such election, as of the date of this prospectus, it
is not possible for us to predict the number of shares of Common Stock that we will sell to Keystone under the ELOC Purchase Agreement,
the actual purchase price per share to be paid by Keystone for those shares of Common Stock, or the actual gross proceeds to be raised
by us from those sales, if any. As of April 24, 2026, there were 11,464,572 shares of Common Stock outstanding. If all of the 25,000,000
shares of our Common Stock offered for resale by the Selling Stockholders under this prospectus were issued and outstanding as of April
24, 2026, such shares would represent approximately 68.8% of the total number of shares of our Common Stock outstanding. The actual number
of shares of our Common Stock issuable will vary depending on the then current market price of shares of our Common Stock sold to the
Selling Stockholder in this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The number of shares of Common
Stock ultimately offered for sale by the Selling Stockholder for resale under this prospectus is dependent upon the number of shares of
Common Stock, if any, we ultimately sell to Keystone under the ELOC Purchase Agreement. Further, if and when we elect to sell shares of
Common Stock to Keystone pursuant to the ELOC Purchase Agreement, after Keystone has acquired such shares, Keystone may resell all, some
or none of such shares of Common Stock at any time or from time to time in its discretion and at different prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The issuance of our shares
of Common Stock to the Selling Stockholder pursuant to the ELOC Purchase Agreement will not affect the rights or privileges of our existing
stockholders, except that the economic and voting interests of each of our existing stockholders will be diluted. Although the number
of shares of Common Stock that our existing stockholders own will not decrease, the shares of Common Stock owned by our existing stockholders
will represent a smaller percentage of our total outstanding shares of Common Stock after any such issuance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Although the ELOC Purchase
Agreement provides that we may sell up to an aggregate of $25.0 million of shares of our Common Stock to Keystone, only 25,000,000 shares
(assuming the shares are sold at a price of $0.6771 per share) are being registered for resale under the registration statement that includes
this prospectus. If it becomes necessary for us to issue and sell more shares than are being registered for resale under this prospectus
in order to receive aggregate gross proceeds equal to $25.0 million under the ELOC Purchase Agreement, we must first file with the SEC
one or more additional registration statements to register under the Securities Act the resale by Keystone of any such additional shares
of our Common Stock we wish to sell from time to time under the ELOC Purchase Agreement, which the SEC must declare effective, in each
case, before we may elect to sell any additional shares of our Common Stock to Keystone under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following table sets
forth the number of shares of Common Stock to be issued to Keystone under the ELOC Purchase Agreement registered hereunder at varying
purchase prices:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Assumed Average <BR> Purchase Price<BR> Per Share</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Number of&nbsp;Registered<BR> Shares to be Issued if<BR> Full Purchase<SUP>(1)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Percentage of <BR> Outstanding Shares <BR> After Giving Effect<BR> to the Issuance to<BR> Keystone<SUP>(2)</SUP></B></FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Gross Proceeds<BR> from the Sale of Shares<BR> to Keystone<BR> Under the<BR> Purchase<BR> Agreement</TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 23%; text-align: right">0.50</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">33,858,886</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">&nbsp;</TD><TD STYLE="width: 22%; text-align: right">74.9</TD><TD STYLE="width: 1%; text-align: left">%</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 22%; text-align: right">16,929,443</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.00</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">16,929,443</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">59.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,929,443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1.50</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">11,286,295</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">49.9</TD><TD STYLE="text-align: left">%</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,929,443</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  </TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Notes to table:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="text-align: justify">The purchase prices assume a discount to the market prices of our shares, in accordance with the ELOC Purchase Agreement.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(2)</TD>
    <TD STYLE="text-align: justify">The denominator is based on 11,464,572 shares outstanding as of April 24, 2026, adjusted to include the number of shares set forth in the adjacent column that we would have sold to Keystone, assuming the average purchase price in the first column. The numerator is based on the number of shares issuable pursuant to future sales under the ELOC Purchase Agreement (that are the subject of this offering) at the corresponding assumed average purchase price set forth in the first column.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We will not receive any proceeds
from the sale of Common Stock by the Selling Stockholder pursuant to this prospectus. We may receive up to $25.0 million in aggregate
gross proceeds from Keystone under the ELOC Purchase Agreement in connection with sales of the shares of our Common Stock pursuant to
the ELOC Purchase Agreement after the date of this prospectus. However, the actual proceeds from Keystone may be less than this amount
depending on the number of shares of our Common Stock sold and the price at which the shares of our Common Stock are sold.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Pursuant to the ELOC Purchase
Agreement, 30% of the gross proceeds to the Company from any sale of Common Stock thereunder must be applied towards the redemption of
the Company&rsquo;s Series C Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Any remaining proceeds we
receive from the sale of Common Stock under the ELOC Purchase Agreement will be used for general corporate and working capital or for
other purposes that the Board, in its good faith, deems to be in the best interest of the Company. Through April 24, 2026, the Company
has sold approximately 701,933 split-adjusted shares under the ELOC Purchase Agreement for aggregate proceeds of approximately $8.1 million.
No assurances can be given that we will receive any further proceeds from sale of Common Stock under the ELOC Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>DETERMINATION OF OFFERING PRICE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder will
offer Common Stock at the prevailing market prices or a privately negotiated price as it may determine from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The offering price of our
Common Stock to be sold by the Selling Stockholder does not necessarily bear any relationship to our book value, assets, past operating
results, financial condition, or any other established criteria of value. The facts considered in determining the offering price were
our financial condition and prospects, our limited operating history and the general condition of the securities market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">In addition, there is no
assurance that our Common Stock will trade at market prices in excess of the offering price as prices for our Common Stock in any public
market will be determined in the marketplace and may be influenced by many factors, including the depth and liquidity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_005"></A>DESCRIPTION OF CAPITAL STOCK</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation authorizes the issuance of up to 250,000,000 shares of Common Stock, $0.00001 par value per share, and 10,000,000
shares of preferred stock, $0.00001 par value per share. As of the date of this prospectus, we have 11,464,572 shares of Common Stock
outstanding, 7 shares of Series C Preferred Stock issued and outstanding, 8,156 shares of Series D Preferred Stock issued and outstanding,
and 0 shares of Series E Preferred Stock issued and outstanding. Our shares of Common Stock are held of record by approximately 17 stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock is listed
on the Nasdaq Capital Market under the symbol &ldquo;ONCO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of our Amended
and Restated Certificate of Incorporation, holders of our Common Stock are entitled to one vote for each share held on all matters submitted
to a vote of stockholders, including the election of directors, and do not have cumulative voting rights. The holders of outstanding shares
of Common Stock are entitled to receive dividends out of assets or funds legally available for the payment of dividends of such times
and in such amounts as our Board from time to time may determine. Our Common Stock is not entitled to pre-emptive rights and is not subject
to conversion or redemption. Upon liquidation, dissolution or winding up of our company, the assets legally available for distribution
to stockholders are distributable ratably among the holders of our Common Stock after payment of liquidation preferences, if any, on any
outstanding payment of other claims of creditors. The rights, preferences and privileges of holders of Common Stock are subject to and
may be adversely affected by the rights of the holders of shares of any series of preferred stock that we may designate and issue in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Preferred Stock and Warrants</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of our Amended
and Restated Certificate of Incorporation, our Board is authorized, without further action by the stockholders, to establish one or more
class or series, and fix the relative rights and preferences of the company&rsquo;s undesignated capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series C Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion Rights</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conversion at Option of
Holder</I>. Each holder is entitled to convert any portion of the outstanding Series C Preferred Stock held by such holder into validly
issued, fully paid and non-assessable Series C Conversion Shares at the Series C Conversion Rate. Except as otherwise provided in the
Series C Certificate of Designations, the number of Conversion Shares issuable upon conversion of any Series C Preferred Share will be
determined by dividing (x) the Conversion Amount of such Series C Share by (y) the Conversion Price (the &ldquo;Series C Conversion Rate&rdquo;).
As used herein, the term &ldquo;Conversion Amount&rdquo; means, with respect to each Series C Preferred Share, as of the applicable date
of determination, the sum of (1) the Stated Value thereof <U>plus</U> (2) any Series C Default Dividends thereon as of such date of determination
<U>plus</U> (3) any other amounts owed to such investor pursuant to the terms of the Series C Certificate of Designations or any other
Transaction Document; and the term &ldquo;Conversion Price&rdquo; means, with respect to each Series C Preferred Share, as of any Conversion
Date or other date of determination, $22.528 on a post-reverse split basis, subject to adjustment as provided in the Series C Certificate
of Designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conversion at the Option
of the Holder Upon the Occurrence of a Triggering Event</I>. After the Stockholder Approval Date (as defined in the Series C Securities
Purchase Agreement), if a Triggering Event occurs and is continuing, at any time after the earlier of a holder&rsquo;s receipt of a Triggering
Event Notice and such holder becoming aware of such Triggering Event (such earlier date, the &ldquo;Alternate Conversion Right Commencement
Date&rdquo;) and ending on the twentieth (20<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>) Trading Day after the later of (x) the
date such Triggering Event is cured and (y) such holder&rsquo;s receipt of a Triggering Event Notice (such ending date, the &ldquo;Alternate
Conversion Right Expiration Date&rdquo;, and each such period, an &ldquo;Alternate Conversion Right Period&rdquo;), such holder may, at
such holder&rsquo;s option, by delivery of a Conversion Notice to the Company (the date of any such Conversion Notice, each an &ldquo;Alternate
Conversion Date&rdquo;), convert all, or any number of Series C Preferred Stock held by such holder into shares of Common Stock at the
Alternate Conversion Price (each, an &ldquo;Alternate Conversion&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein with respect to the Series C Preferred
Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Alternate Conversion
Price</I>&rdquo; means, with respect to any Alternate Conversion that price which will be the lowest of (i) the applicable Conversion
Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the Floor Price
and (y) 80% of the lowest VWAP of the Common Stock during the five (5) consecutive Trading Day period ending and including the Trading
Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice (such period, the &ldquo;Alternate Conversion
Measuring Period&rdquo;). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination,
reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate Conversion
Measuring Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Alternate Conversion
Floor Amount</I>&rdquo; means an amount equal to the product obtained by multiplying (A) the higher of (i) the highest price that the
Common Stock trades at on the Trading Day immediately preceding the relevant Alternate Conversion Date and (ii) the applicable Alternate
Conversion Price and (B) the difference obtained by subtracting (i) the number of shares of Common Stock delivered (or to be delivered)
to such holder on the applicable Share Delivery Deadline with respect to such Alternate Conversion from (ii) the quotient obtained by
dividing (x) the applicable Conversion Amount that such holder has elected to be the subject of the applicable Alternate Conversion, by
(y) the applicable Alternate Conversion Price, without giving effect to the Floor Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Floor Price</I>&rdquo;
means $5.00 (as adjusted for stock splits, stock dividends, stock combinations, recapitalizations and similar events), or, subject to
the rules and regulations of the Principal Market, such lower price as the Company and the Required Holders may agree, from time to time.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Triggering Event
Notice</I>&rdquo; means written notice from the Company delivered to each holder within two Business Days after the occurrence of a Triggering
Event) that includes (i) a reasonable description of the applicable Triggering Event, (ii) a certification as to whether, in the reasonable
opinion of the Company, such Triggering Event is capable of being cured and, if applicable, a reasonable description of any existing plans
of the Company to cure such Triggering Event and (iii) a certification as to the date the Triggering Event occurred and, if cured on or
prior to the date of such Triggering Event Notice, the applicable Alternate Conversion Right Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Triggering Event</I>&rdquo;
includes, but is not limited to, the following, subject to certain cure periods as set forth in the Series C Certificate of Designations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(i) the failure
to file a registration statement for the resale of the shares of Common Stock underlying the Series C Preferred Stock and the Series C
Warrants, or the failure of the applicable Registration Statement to be declared effective by the SEC, ten (10) days after the applicable
deadline;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(ii) the failure
to maintain the effectiveness of a registration statement pursuant to the terms of the Registration Rights Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(iii) the suspension
from trading or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5)
consecutive Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(iv) failure to
cure a Conversion Failure or a Delivery Failure (as defined in the Series C Warrants) by delivery of the required number of shares of
Common Stock within the requisite time frame;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(v) failure to
maintain authorized, but unissued shares equal to 150% of the shares underlying the Series C Preferred Stock and the Series C Warrants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(vi) the occurrence
of any default under, redemption of or acceleration prior to maturity of at least an aggregate of $500,000 of Indebtedness of the Company
or any of its Subsidiaries, or a final judgment or judgments for the payment of money aggregating in excess of $500,000 are rendered against
the Company and/or any of its Subsidiaries;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(vii) the institution,
commencement, court order or decree by or against the Company or any Subsidiary of certain bankruptcy, insolvency, reorganization or liquidation
proceedings or other proceedings for the relief of debtors (the &ldquo;Bankruptcy Triggering Events&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(viii) the Company
and/or any Subsidiary, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period, any
payment with respect to any Indebtedness in excess of $500,000 due to any third party (other than, with respect to unsecured Indebtedness
only, payments contested by the Company and/or such Subsidiary (as the case may be) in good faith by proper proceedings and with respect
to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation
of any agreement for monies owed or owing in an amount in excess of $500,000, which breach or violation permits the other party thereto
to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffer to exist any other circumstance or event that would,
with or without the passage of time or the giving of notice, result in a default or event of default under any agreement binding the Company
or any Subsidiary, which default or event of default would or is likely to have a material adverse effect on the business, assets, operations
(including results thereof), liabilities, properties, condition (including financial condition) or prospects of the Company or any of
its Subsidiaries, individually or in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(ix) the Company
or any Subsidiary breaches any representation or warranty in any material respect (other than representations or warranties subject to
Material Adverse Effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction
Document;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(x) a false or
inaccurate certification (including a false or inaccurate deemed certification) by the Company that either (A) the Equity Conditions are
satisfied, (B) there has been no Equity Conditions Failure, or (C) as to whether any Triggering Event has occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xi) any breach
or failure in any respect by the Company or any Subsidiary to comply with any provision of the covenants included in the Series C Certificate
of Designations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xii) any Series
C Preferred Stock remain outstanding on or after April 2, 2026;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xiii) any Change
of Control occurs without the prior written consent of the Required Holders, which consent will not be unreasonably withheld, conditioned
or delayed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xiv) any Material
Adverse Effect occurs; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xv) any provision
of any Transaction Document will at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding
on or enforceable against the Company, or the validity or enforceability thereof is contested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conversion Price Adjustments</I>.
If on the ninetieth (90th) calendar day and one hundred eightieth (180) calendar day (each an &ldquo;Adjustment Date&rdquo;) following
the occurrence of the later of (x) the date that Company stockholders approve the transaction and all securities issuable to the Series
C PIPE Investors in connection therewith, as required by Nasdaq (&ldquo;Stockholder Approval&rdquo;) and (y) the earlier of (a) the effective
date of the registration statement to be filed pursuant to the Registration Rights Agreement and (b) the date that the Series C Preferred
Stock is eligible to be resold without restriction under Rule 144 of the Securities Act, as amended (the &ldquo;Securities Act&rdquo;),
the Conversion Price then in effect is greater than the Market Price then in effect (the &ldquo;Adjustment Price&rdquo;), the Conversion
Price will automatically lower to the Adjustment Price. As used herein, &ldquo;Market Price&rdquo; means, with respect to any Adjustment
Date, the greater of (x) the Floor Price and (y) the lowest closing price of the Common Stock on the Principal Market on any Trading Day
during the five (5) Trading Day period ended on, and including, the Trading Day ended immediately prior to such applicable Adjustment
Date (each, a &ldquo;Market Price Measuring Period&rdquo;). All such determinations to be appropriately adjusted for any stock dividend,
stock split, stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during
such applicable Market Price Measuring Period. Only downward adjustments will be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Share Combination Event
Adjustment</I>. In addition to the adjustments set forth above, if at any time and from time to time on or after Stockholder Approval,
there occurs any share split, share dividend, share combination recapitalization or other similar transaction involving the Common Stock
(each, a &ldquo;Share Combination Event&rdquo;, and such date thereof, the &ldquo;Share Combination Event Date&rdquo;) and the lowest
VWAP during the ten consecutive (10) Trading Day period ending and including the fifth (5) Trading Day immediately preceding the Share
Combination Event Date (the &ldquo;Event Market Price&rdquo;) (provided if the Share Combination Event is effective after close of trading
on the primary Trading Market, then commencing on the next Trading Day which period will be the &ldquo;Share Combination Adjustment Period&rdquo;)
is less than the Conversion Price then in effect, then at the close of trading on the primary Trading Market on the last day of the Share
Combination Adjustment Period, the Conversion Price then in effect on such fifth (5th) Trading Day will be reduced (but in no event increased)
to the Event Market Price, but not less than the Floor Price. Notwithstanding the foregoing, if one or more Share Combination Events occur
prior to Stockholder Approval being obtained and a reduction of the Conversion Price did not occur, once Stockholder Approval is obtained,
the Conversion Price will automatically be reduced to equal the lowest Event Market Price with respect to any Share Combination Event
that occurred prior to Stockholder Approval being obtained, but not less than the Floor Price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Adjustments for Dilutive
Issuances or Variable Price Securities</I>. If and whenever the Company grants, issues or sells (or enters into any agreement to grant,
issue or sell), or pursuant to the provisions of the Series C Certificate of Designations is deemed to have done any of the foregoing,
but excluding any Excluded Securities granted, issued or sold or deemed to have been granted, issued or sold, any shares of Common Stock
for a consideration price per share (the &ldquo;New Issuance Price&rdquo;) less than a price equal to the Conversion Price in effect immediately
prior to such granting, issuance or sale (such Conversion Price then in effect is referred to herein as the &ldquo;Applicable Price&rdquo;)
(the foregoing a &ldquo;Dilutive Issuance&rdquo;), then, immediately after such Dilutive Issuance, the Conversion Price then in effect
will be reduced to an amount equal to the New Issuance Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if the Company
grants, issues or sells (or enters into any agreement to grant, issue or sell) securities that are issuable pursuant to such agreement
or convertible into or exchangeable or exercisable for shares of Common Stock at a price which varies or may vary with the market price
of the shares of Common Stock, including by way of one or more reset(s) to a fixed price, (each of the formulations for such variable
price being herein referred to as, the &ldquo;Variable Price&rdquo;), the holder shall have the right, but not the obligation, in its
sole discretion to substitute the Variable Price for the Conversion Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Voluntary Adjustment Right</I>.
Subject to the rules and regulations of the Principal Market, the Company has the right, at any time, with the written consent of the
Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate by the Company board
of directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Change of Control Exchange</I>.
Upon a change of control of the Company, each holder may require the Company to exchange the holder&rsquo;s shares of Series C Preferred
Stock for consideration equal to the change of Control Election Price, to be satisfied at the Company&rsquo;s election in either (x) cash
or (y) rights convertible into such securities or other assets to which such holder would have been entitled with respect to such shares
of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Fundamental Transactions.
</I>The Series C Certificate of Designations prohibits the Company from entering specified fundamental transactions (including, without
limitation, mergers, business combinations and similar transactions) unless the Company (or the Company&rsquo;s successor) assumes in
writing all of the Company&rsquo;s obligations under the of Common Stock, except as provided in the transaction documents in connection
with the Series C Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Redemption Rights:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Optional Redemption by
the Company. </I>At any time, the Company has the right to redeem in cash all, but not less than all, of the Series C Preferred Stock
then outstanding at a price (the &ldquo;Company Optional Redemption Price&rdquo;) equal to 125% of the greater of (i) the Conversion Amount
being redeemed and (ii) the product of (1) the Series C Conversion Rate with respect to the Conversion Amount being redeemed multiplied
by (2) the greatest closing sale price of the Company&rsquo;s Common Stock on any Trading Day during the period commencing on the date
immediately preceding the date the Company notifies the holders of its election to redeem and the date the Company makes the entire payment
required.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Mandatory Redemption by
the Company Upon a Bankruptcy Triggering Event. </I>Upon the occurrence and continuation of a Bankruptcy Triggering Event, the Company
will immediately redeem, in cash, each of the Series C Preferred Stock then outstanding at a redemption price equal to the greater of
(i) the product of (A) the Conversion Amount to be redeemed multiplied by (B) 125% and (ii) the product of (X) the Series C Conversion
Rate with respect to the Conversion Amount in effect immediately following the date of initial public announcement (or public filing of
bankruptcy documents, as applicable) of such Bankruptcy Triggering Event multiplied by (Y) the product of (1) 125% multiplied by (2) the
greatest closing sale price of the Common Stock on any Trading Day during the period commencing on the date immediately preceding such
Bankruptcy Triggering Event and ending on the date the Company pays the entire payment required, provided that a Holder may, in its sole
discretion, waive such right to receive payment upon a Bankruptcy Triggering Event, in whole or in part, and any such waiver will not
affect any other rights of such Holder or any other Holder hereunder, including any other rights in respect of such Bankruptcy Triggering
Event or any right to conversion (or Alternate Conversion), as applicable.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Voting Rights</I>. The
holders of the Series C Preferred Stock have no voting power and no right to vote on any matter at any time, either as a separate series
or class or together with any other series or class of share of capital stock, and are not entitled to call a meeting of such holders
for any purpose nor are they entitled to participate in any meeting of the holders of Common Stock, except as provided in the Series C
Certificate of Designations (or as otherwise required by applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Covenants</I>. The Series
C Certificate of Designations contains a variety of obligations on the Company&rsquo;s part not to engage in specified activities, which
are typical for transactions of this type. In particular, the Company will not, and will cause the Company&rsquo;s subsidiaries to not,
redeem, repurchase or declare any dividend or distribution on any of its capital stock (other than as required under the Series C Certificate
of Designations). In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach
or default under the of Series C Certificate of Designations or Series C Warrants.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Ownership Limitation.
</I>In no event may any Series C Preferred Stock be converted (or Series C Warrants be exercised) and shares of Common Stock be issued
to any holder if after giving effect to the issuance of shares of Common Stock upon such conversion of the Series C Preferred Stock (or
exercise of the Series C Warrants), the holder (together with its affiliates, if any) would beneficially own more than 4.99% of the outstanding
shares of Common Stock, which we refer to herein as the &ldquo;Series C PIPE Blocker&rdquo;). The Series C PIPE Blocker may be raised
or lowered to any other percentage not in excess of 9.99% at the option of the applicable holder of the Series C Preferred Stock (or Series
C Warrants), except that any raise will only be effective upon 61-days&rsquo; prior notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exchange Right. </I>If
the Company or any of its Subsidiaries consummates any Subsequent Placement (other than with respect to Excluded Securities (as defined
in the Securities Purchase Agreement)), and a holder elects in writing to the Company to participate in such Subsequent Placement, each
such holder may, at the option of such holder as elected in writing to the Company, exchange all, or any part, of the Series C Preferred
Stock of such holder into the securities in such Subsequent Placement (with the aggregate amount of such securities to be issued in such
exchange equal to such aggregate amount of such securities with a purchase price valued at 120% of the Conversion Amount of the Series
C Preferred Stock delivered by such holder in exchange therefor); provided that any such exchange will be subject to all applicable Nasdaq
restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Reservation Requirements.
</I>So long as any Series C Preferred Stock remains outstanding, the Company will at all times reserve at least 150% of the number of
shares of Common Stock as will from time to time be necessary to effect the conversion of all Series C Preferred Stock then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conditions Precedent to
Closing</I>: As set forth in the Securities Purchase Agreement, the obligations of each party to consummate the transactions in connection
Series C Securities Purchase Agreement are conditioned upon, among other things, customary closing conditions and the consummation of
the transactions contemplated by the committed equity line of credit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Series C Warrants </I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercise Price</I>. The
exercise price of the Series C Warrants on a post-reverse split basis is $1,862.50, the Nasdaq Minimum Price (as defined below.) The exercise
price is subject to adjustment for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the
number of shares of Common Stock issuable upon the exercise of the Series C Warrant also will be adjusted so that the aggregate exercise
price will be the same immediately before and immediately after any such adjustment.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercise Price Adjustments</I>.
If on an Adjustment Date, the exercise price then in effect is greater than the Market Price then in effect (the &ldquo;Warrant Adjustment
Price&rdquo;), the exercise price will automatically lower to the Warrant Adjustment Price. As used herein, &ldquo;Market Price&rdquo;
means, with respect to any Adjustment Date, the greater of (x) the Floor Price and (y) the lowest closing price of the Common Stock on
the Principal Market on any Trading Day during the five (5) Trading Day period ended on, and including, the Trading Day ended immediately
prior to such applicable Adjustment Date (each, a &ldquo;Market Price Measuring Period&rdquo;). All such determinations to be appropriately
adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction that proportionately decreases
or increases the Common Stock during such applicable Market Price Measuring Period. Only downward adjustments will be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Adjustments for Dilutive
Issuances or Variable Price Securities</I>. If and whenever the Company grants, issues or sells (or enters into any agreement to grant,
issue or sell), or pursuant to the provisions of the Series C Warrant is deemed to have done any of the foregoing, but excluding any Excluded
Securities granted, issued or sold or deemed to have been granted, issued or sold any shares of Common Stock for a consideration price
per share (the &ldquo;Warrant New Issuance Price&rdquo;) less than a price equal to the exercise price in effect immediately prior to
such granting, issuance or sale (the foregoing a &ldquo;Warrant Dilutive Issuance&rdquo;), then, immediately after such Warrant Dilutive
Issuance, the exercise price then in effect will be reduced to an amount equal to the Warrant New Issuance Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if the Company
grants, issues or sells (or enters into any agreement to grant, issue or sell) securities at a Variable Price, the warrant holder shall
have the right, but not the obligation, in its sole discretion to exercise the Series C Warrants at the Variable Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercise Period</I>. The
Series C Warrants are exercisable beginning six months after the issuance date (the &ldquo;Initial Exercisability Date&rdquo;) and expiring
on the third anniversary of the Initial Exercisability Date. The Series C Warrants require &ldquo;buy-in&rdquo; payments to be made by
us for failure to deliver any shares of Common Stock issuable upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Cashless Exercise</I>.
If at the time of exercise of the Series C Warrants, there is no effective registration statement registering the shares of the Common
Stock underlying the Series C Warrants, such Series C Warrants may be exercised on a cashless basis pursuant to their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Purchase Rights; Participation
Rights</I>. If the Company issues options, convertible securities, warrants, shares, or similar securities to holders of the Company shares
of the Common Stock, each holder of the Series C Warrant has the right to acquire the same as if the holder had exercised its Series C
Warrant. The holders of the Series C Warrants are entitled to receive any dividends paid or distributions made to the holders of the Company&rsquo;s
shares of Common Stock on an &ldquo;as if converted&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Fundamental Transactions</I>.
The Series C Warrants prohibit the Company from entering into specified fundamental transactions unless the successor entity assumes all
of the Company obligations under the Series C Warrants under a written agreement before the transaction is completed. Upon specified corporate
events, a Series C Warrant holder will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or
any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event
had the Series C Warrant been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified
changes of control, a Series C Warrant holder will have the right to force the Company to repurchase the holder&rsquo;s Series C Warrant
for a purchase price in cash equal to the Black Scholes value, as calculated under the Series C Warrants, of the then unexercised portion
of the Series C Warrant.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Series D Certificate of Designations</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>General<B>. </B></I>Pursuant
to the Series D Certificate of Designations, the Company has authorized the issuance of up to 32,000 shares of Series D Preferred Stock,
each having a stated value of $1,000 per share (the &ldquo;Series D Stated Value&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Ranking. </I>Except (i)
for the Series C Preferred Stock of the Company, which shall be of pari passu rank to the Series D Preferred Stock (the &ldquo;Series
D Parity Stock&rdquo;), and (ii) to the extent that the Required Holders (as defined in the Series D Securities Purchase Agreement) expressly
consent to the creation of Parity Stock or Senior Preferred Stock, all shares of capital stock of the Company will be junior in rank to
all Series D Preferred Stock with respect to the preferences as to dividends, distributions and payments upon the liquidation, dissolution
and winding up of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Dividends. </I>The holders
of Series D Preferred Stock are entitled to dividends (the &ldquo;Series D Dividends&rdquo;), when and as declared by the Board, from
time to time, in its sole discretion, which Series D Dividends shall be paid by the Company out of funds legally available therefor, payable,
subject to the conditions and other terms hereof, in cash, in securities of the Company or any other entity, or using assets as determined
by the Board on the Series D Stated Value of such Series D Preferred Share. In addition, from and after the occurrence and during the
continuance of any Triggering Event, dividends (&ldquo;Series D Default Dividends&rdquo;) will accrue on the Series D Stated Value of
each Series D Preferred Share at a rate of fifteen percent (15.0%) (the &ldquo;Series D Default Rate&rdquo;) per annum. Series D Default
Dividends are payable by way of inclusion of Series D Default Dividends in the Conversion Amount (as defined below) on each conversion
date. In the event that such Triggering Event is subsequently cured (and no other Triggering Event then exists), the accrual of Series
D Default Dividends will cease to be effective as of the calendar day immediately following the date of such cure; provided that Series
D Default Dividends as calculated and unpaid during the continuance of such Triggering Event will continue to apply to the extent relating
to the days after the occurrence of such Triggering Event through and including the date of such cure of such Triggering Event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Conversion Rights</I>:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conversion at Option of
Holder. </I>Each holder is entitled to convert any portion of the outstanding Series D Preferred Stock held by such holder into validly
issued, fully paid and non-assessable Conversion Shares at the Series D Conversion Rate (as defined below). Except as otherwise provided
in the Series D Certificate of Designations, the number of Conversion Shares issuable upon conversion of any Series D Preferred Share
will be determined by dividing (x) the Conversion Amount (as defined below) of such Series D Preferred Share by (y) the Conversion Price
(the &ldquo;Series D Conversion Rate&rdquo;). As used herein, the term &ldquo;Conversion Amount&rdquo; means, with respect to each Series
D Preferred Share, as of the applicable date of determination, the sum of (1) the Series D Stated Value thereof <U>plus</U> (2) any Series
D Default Dividends thereon as of such date of determination <U>plus</U> (3) any other amounts owed to such investor pursuant to the terms
of the Series D Certificate of Designations or any other Transaction Document; and the term &ldquo;Conversion Price&rdquo; means, with
respect to each Series D Preferred Share, as of any Conversion Date or other date of determination, $18.448 on a post-reverse split basis,
subject to adjustment as provided in the Series D Certificate of Designations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conversion at the Option
of the Holder Upon the Occurrence of a Triggering Event</I>. After the Stockholder Approval Date (as defined in the Series D Securities
Purchase Agreement), if a Triggering Event occurs and is continuing, at any time after the earlier of a holder&rsquo;s receipt of a Triggering
Event Notice (as defined below) and such holder becoming aware of such Triggering Event (such earlier date, the &ldquo;Alternate Conversion
Right Commencement Date&rdquo;) and ending on the twentieth (20<FONT STYLE="font-size: 10pt"><SUP>th</SUP></FONT>) Trading Day (as defined
in the Series D Securities Purchase Agreement) after the later of (x) the date such Triggering Event is cured and (y) such holder&rsquo;s
receipt of a Triggering Event Notice (such ending date, the &ldquo;Alternate Conversion Right Expiration Date&rdquo;, and each such period,
an &ldquo;Alternate Conversion Right Period&rdquo;), such holder may, at such holder&rsquo;s option, by delivery of a Conversion Notice
to the Company (the date of any such Conversion Notice, each an &ldquo;Alternate Conversion Date&rdquo;), convert all, or any number of
Series D Preferred Stock held by such holder into shares of Common Stock at the Alternate Conversion Price (each, an &ldquo;Alternate
Conversion&rdquo;). Additionally, at any time after the Stockholder Approval Date, the Holder may convert any number of Series D Preferred
Stock held by such Holder at the Alternate Optional Conversion Price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As used herein with respect to the Series D Preferred
Stock:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Alternate Conversion
Price</I>&rdquo; means, with respect to any Alternate Conversion that price which will be the lowest of (i) the applicable Conversion
Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the Floor Price
(as defined below) and (y) 90% of the lowest VWAP of the Common Stock during the five (5) consecutive Trading Day period ending and including
the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice (such period, the &ldquo;<I>Alternate
Conversion Measuring Period</I>&rdquo;). All such determinations to be appropriately adjusted for any stock dividend, stock split, stock
combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate
Conversion Measuring Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Alternate Conversion
Floor Amount</I>&rdquo; means an amount equal to the product obtained by multiplying (A) the higher of (i) the highest price that the
Common Stock trades at on the Trading Day immediately preceding the relevant Alternate Conversion Date and (ii) the applicable Alternate
Conversion Price and (B) the difference obtained by subtracting (i) the number of shares of Common Stock delivered (or to be delivered)
to such holder on the applicable Share Delivery Deadline (as defined in the Series D Certificate of Designations) with respect to such
Alternate Conversion from (ii) the quotient obtained by dividing (x) the applicable Conversion Amount that such holder has elected to
be the subject of the applicable Alternate Conversion, by (y) the applicable Alternate Conversion Price, without giving effect to the
Floor Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Alternate Optional
Conversion Price</I>&rdquo; means, with respect to any Alternate Conversion that price which will be the lowest of (i) the applicable
Conversion Price as in effect on the applicable Conversion Date of the applicable Alternate Conversion, and (ii) the greater of (x) the
Floor Price and (y) 95% of the lowest VWAP of the Common Stock during the five (5) consecutive Trading Day period ending and including
the Trading Day immediately preceding the delivery or deemed delivery of the applicable Conversion Notice (such period, the &ldquo;<I>Alternate
Optional Conversion Measuring Period</I>&rdquo;). All such determinations to be appropriately adjusted for any stock dividend, stock split,
stock combination, reclassification or similar transaction that proportionately decreases or increases the Common Stock during such Alternate
Optional Conversion Measuring Period.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Floor Price</I>&rdquo;
means $0.5322 on a post-reverse split and post-adjustment date basis (as adjusted for stock splits, stock dividends, stock combinations,
recapitalizations and similar events), or, subject to the rules and regulations of the Principal Market (as defined in the Series D Certificate
of Designations), such lower price as the Company and the Required Holders may agree, from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Triggering Event
Notice</I>&rdquo; means written notice from the Company delivered to each holder within two Business Days (as defined in the Series D
Securities Purchase Agreement) after the occurrence of a Triggering Event) that includes (i) a reasonable description of the applicable
Triggering Event, (ii) a certification as to whether, in the reasonable opinion of the Company, such Triggering Event is capable of being
cured and, if applicable, a reasonable description of any existing plans of the Company to cure such Triggering Event and (iii) a certification
as to the date the Triggering Event occurred and, if cured on or prior to the date of such Triggering Event Notice, the applicable Alternate
Conversion Right Expiration Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&ldquo;<I>Triggering Event</I>&rdquo;
includes, but is not limited to, the following, subject to certain cure periods as set forth in the Series D Certificate of Designations:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(i) the failure
to file a registration statement for the resale of the shares of Common Stock underlying the Series D Preferred Stock and the Warrants,
or the failure of the applicable registration statement to be declared effective by the SEC, ten (10) days after the applicable deadline;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(ii) the failure
to maintain the effectiveness of a registration statement pursuant to the terms of the Registration Rights Agreement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(iii) the suspension
from trading or the failure of the Common Stock to be trading or listed (as applicable) on an Eligible Market for a period of five (5)
consecutive Trading Days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(iv) failure to
cure a Conversion Failure or a Delivery Failure (as defined in the Warrants) by delivery of the required number of shares of Common Stock
within the requisite time frame;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(v) failure to
maintain authorized, but unissued shares equal to 150% of the shares underlying the Series D Preferred Stock and the Warrants;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(vi) failure to
remove any restrictive legend on any certificate or any shares of Common Stock issued to the applicable Holder upon conversion or exercise
(as the case may be) of any Securities (as defined in the Series D Securities Purchase Agreement) acquired by such Holder under the Transaction
Documents as and when required by such Securities or the Series D Securities Purchase Agreement, as applicable, unless otherwise then
prohibited by applicable federal securities laws, and any such failure remains uncured for at least five (5) days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(vii) the occurrence
of any default under, redemption of or acceleration prior to maturity of at least an aggregate of $500,000 of Indebtedness of the Company
or any of its Subsidiaries (as defined in the Series D Securities Purchase Agreement);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(viii) the institution,
commencement, court order or decree by or against the Company or any Subsidiary of certain bankruptcy, insolvency, reorganization or liquidation
proceedings or other proceedings for the relief of debtors;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(ix) the commencement
by the Company or any Subsidiary of a voluntary case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency,
reorganization or other similar law or of any other case or proceeding to be adjudicated a bankrupt or insolvent, or the consent by it
to the entry of a decree, order, judgment or other similar document in respect of the Company or any Subsidiary in an involuntary case
or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or to the commencement
of any bankruptcy or insolvency case or proceeding against it, or the filing by it of a petition or answer or consent seeking reorganization
or relief under any applicable federal, state or foreign law, or the consent by it to the filing of such petition or to the appointment
of or taking possession by a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company
or any Subsidiary or of any substantial part of its property, or the making by it of an assignment for the benefit of creditors, or the
execution of a composition of debts, or the occurrence of any other similar federal, state or foreign proceeding, or the admission by
it in writing of its inability to pay its debts generally as they become due, the taking of corporate action by the Company or any Subsidiary
in furtherance of any such action or the taking of any action by any Person to commence a Uniform Commercial Code foreclosure sale or
any other similar action under federal, state or foreign law;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(x) the entry by
a court of (i) a decree, order, judgment or other similar document in respect of the Company or any Subsidiary of a voluntary or involuntary
case or proceeding under any applicable federal, state or foreign bankruptcy, insolvency, reorganization or other similar law or (ii)
a decree, order, judgment or other similar document adjudging the Company or any Subsidiary as bankrupt or insolvent, or approving as
properly filed a petition seeking liquidation, reorganization, arrangement, adjustment or composition of or in respect of the Company
or any Subsidiary under any applicable federal, state or foreign law or (iii) a decree, order, judgment or other similar document appointing
a custodian, receiver, liquidator, assignee, trustee, sequestrator or other similar official of the Company or any Subsidiary or of any
substantial part of its property, or ordering the winding up or liquidation of its affairs, and the continuance of any such decree, order,
judgment or other similar document or any such other decree, order, judgment or other similar document unstayed and in effect for a period
of forty-five (45) consecutive days;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xi) a final judgment
or judgments for the payment of money aggregating in excess of $500,000 are rendered against the Company and/or any of its Subsidiaries
and which judgments are not, within forty-five (45) days after the entry thereof, bonded, discharged, settled or stayed pending appeal,
or are not discharged within forty-five (45) days after the expiration of such stay; provided, however, any judgment which is covered
by insurance or an indemnity from a credit worthy party shall not be included in calculating the $500,000 amount set forth above so long
as the Company provides each Holder a written statement from such insurer or indemnity provider (which written statement shall be reasonably
satisfactory to each Holder) to the effect that such judgment is covered by insurance or an indemnity and the Company or such Subsidiary
(as the case may be) will receive the proceeds of such insurance or indemnity within forty-five (45) days of the issuance of such judgment;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xii) the Company
and/or any Subsidiary, individually or in the aggregate, either (i) fails to pay, when due, or within any applicable grace period, any
payment with respect to any Indebtedness in excess of $500,000 due to any third party (other than, with respect to unsecured Indebtedness
only, payments contested by the Company and/or such Subsidiary (as the case may be) in good faith by proper proceedings and with respect
to which adequate reserves have been set aside for the payment thereof in accordance with GAAP) or is otherwise in breach or violation
of any agreement for monies owed or owing in an amount in excess of $500,000, which breach or violation permits the other party thereto
to declare a default or otherwise accelerate amounts due thereunder, or (ii) suffer to exist any other circumstance or event that would,
with or without the passage of time or the giving of notice, result in a default or event of default under any agreement binding the Company
or any Subsidiary, which default or event of default would or is likely to have a material adverse effect on the business, assets, operations
(including results thereof), liabilities, properties, condition (including financial condition) or prospects of the Company or any of
its Subsidiaries, individually or in the aggregate;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xiii) the Company
or any Subsidiary breaches any representation or warranty in any material respect (other than representations or warranties subject to
Material Adverse Effect or materiality, which may not be breached in any respect) or any covenant or other term or condition of any Transaction
Document, except, in the case of a breach of a covenant or other term or condition that is curable, only if such breach remains uncured
for a period of five (5) consecutive Trading Days;&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xiv) a false or
inaccurate certification (including a false or inaccurate deemed certification) by the Company that either (A) the Equity Conditions are
satisfied, (B) there has been no Equity Conditions Failure, or (C) as to whether any Triggering Event has occurred;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xv) any breach
or failure in any respect by the Company or any Subsidiary to comply with any provision of the covenants listed in the Series D Certificate
of Designations;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xvi) any Series
D Preferred Stock remain outstanding on or after March 23, 2027;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xvii) any Change
of Control occurs without the prior written consent of the Required Holders, which consent will not be unreasonably withheld, conditioned
or delayed;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xviii) any Material
Adverse Effect occurs; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.25in">(xix) any provision
of any Transaction Document will at any time for any reason (other than pursuant to the express terms thereof) cease to be valid and binding
on or enforceable against the Company, or the validity or enforceability thereof is contested.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Stock Combination Event
Adjustment<B>.</B></I> In addition to the adjustments set forth above, if at any time and from time to time on or after Stockholder Approval,
there occurs any share split, share dividend, stock combination recapitalization or other similar transaction involving the Common Stock
(each, a &ldquo;Stock Combination Event&rdquo;, and such date thereof, the &ldquo;Stock Combination Event Date&rdquo;) and the lowest
VWAP during the ten consecutive (10) Trading Day period ending and including the fifth (5) Trading Day immediately preceding the Stock
Combination Event Date (the &ldquo;Event Market Price&rdquo;) (provided if the Stock Combination Event is effective after close of trading
on the primary Trading Market, then commencing on the next Trading Day which period will be the &ldquo;Stock Combination Adjustment Period&rdquo;)
is less than the Conversion Price then in effect, then at the close of trading on the primary Trading Market on the last day of the Stock
Combination Adjustment Period, the Conversion Price then in effect on such fifth (5th) Trading Day will be reduced (but in no event increased)
to the Event Market Price, but not less than the Floor Price. Notwithstanding the foregoing, if one or more Stock Combination Events occur
prior to Stockholder Approval being obtained and a reduction of the Conversion Price did not occur, once Stockholder Approval is obtained,
the Conversion Price will automatically be reduced to equal the lowest Event Market Price with respect to any Stock Combination Event
that occurred prior to Stockholder Approval being obtained, but not less than the Floor Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Adjustments for Variable
Price Security Issuances</I>. If the Company in any manner issues or sells or enters into any agreement to issue or sell, any Common Stock,
Options or Convertible Securities (other than with respect to a Permitted Equity Line (as defined in the Series D Securities Purchase
Agreement)) (any such securities, &ldquo;Variable Price Securities&rdquo;) after the Subscription Date (as defined in the Series D Certificate
of Designations) that are issuable pursuant to such agreement or convertible into or exchangeable or exercisable for shares of Common
Stock at a price which varies or may vary with the market price of the shares of Common Stock, including by way of one or more reset(s)
to a fixed price, but exclusive of such formulations reflecting share splits, share combinations and share dividends (each of the formulations
for such variable price being herein referred to as, the &ldquo;Variable Price&rdquo;), the Company shall provide written notice thereof
via electronic mail and overnight courier to each Holder on the date of such agreement and/or the issuance of such shares of Common Stock,
Convertible Securities or Options, as applicable. From and after the date the Company enters into such agreement or issues any such Variable
Price Securities, each Holder shall have the right, but not the obligation, in its sole discretion to substitute the Variable Price for
the Conversion Price upon conversion of the Series D Preferred Stock by designating in the Conversion Notice delivered upon any conversion
of Series D Preferred Stock that solely for purposes of such conversion such Holder is relying on the Variable Price rather than the Conversion
Price then in effect. A Holder&rsquo;s election to rely on a Variable Price for a particular conversion of Series D Preferred Stock shall
not obligate such Holder to rely on a Variable Price for any future conversions of Series D Preferred Stock. &nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Adjustments for Dilutive
Issuances</I>. If and whenever the Company grants, issues or sells (or enters into any agreement to grant, issue or sell), or pursuant
to the provisions of the Series D Certificate of Designations is deemed to have done any of the foregoing, but excluding any Excluded
Securities (as defined in the Series D Certificate of Designations) granted, issued or sold or deemed to have been granted, issued or
sold, any shares of Common Stock for a consideration per share (the &ldquo;New Issuance Price&rdquo;) less than a price equal to the Conversion
Price in effect immediately prior to such granting, issuance or sale (such Conversion Price then in effect is referred to herein as the
&ldquo;<B>Applicable Price</B>&rdquo;) (the foregoing a &ldquo;Dilutive Issuance&rdquo;), then, immediately after such Dilutive Issuance,
the Conversion Price then in effect will be reduced to an amount equal to the New Issuance Price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Voluntary Adjustment Right.
</I>Subject to the rules and regulations of the Principal Market, the Company has the right, at any time, with the written consent of
the Required Holders, to lower the fixed conversion price to any amount and for any period of time deemed appropriate by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Change of Control Exchange.</I>
Upon a change of control of the Company, each holder may require the Company to exchange the holder&rsquo;s shares of Series D Preferred
Stock for consideration equal to the change of Control Election Price, to be satisfied at the Company&rsquo;s election in either (x) cash
or (y) rights convertible into such securities or other assets to which such holder would have been entitled with respect to such shares
of Common Stock had such shares of Common Stock been held by such holder upon consummation of such corporate event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Fundamental Transactions.
</I>The Series D Certificate of Designations prohibits the Company from entering specified fundamental transactions (including, without
limitation, mergers, business combinations and similar transactions) unless the Company (or the Company&rsquo;s successor) assumes in
writing all of the Company&rsquo;s obligations under the of Common Stock, except as provided in the transaction documents in connection
with the Series D Securities Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Redemption Rights:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Optional Redemption by
the Company. </I>At any time, the Company shall have the right to redeem all, or any part pro rata based on the number of the Preferred
Shares then held by the Holders, of the Series D Preferred Stock then outstanding (the &ldquo;Company Optional Redemption Amount&rdquo;)
on the Company Optional Redemption Date (a &ldquo;Company Optional Redemption&rdquo;). The Series D Preferred Stock subject to redemption
shall be redeemed by the Company in cash at a price (the &ldquo;Company Optional Redemption Price&rdquo;) equal to 25% premium on the
greater of (i) the Conversion Amount being redeemed as of the Company Optional Redemption Date and (ii) the product of (1) the Series
D Conversion Rate with respect to the Conversion Amount being redeemed as of the Company Optional Redemption Date (as defined in the Series
D Certificate of Designations) multiplied by (2) the greatest Closing Sale Price of the Common Stock on any Trading Day during the period
commencing on the date immediately preceding such Company Optional Redemption Notice Date (as defined in the Series D Certificate of Designations)
and ending on the Trading Day immediately prior to the date the Company makes the entire payment required to be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Voting Rights</I>. The
holders of the Series D Preferred Stock have no voting power and no right to vote on any matter at any time, either as a separate series
or class or together with any other series or class of share of capital stock, and are not entitled to call a meeting of such holders
for any purpose nor are they entitled to participate in any meeting of the holders of Common Stock, except as provided in the Series D
Certificate of Designations (or as otherwise required by applicable law).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Covenants</I>. The Series
D Certificate of Designations contains a variety of obligations on the Company&rsquo;s part not to engage in specified activities, which
are typical for transactions of this type. In particular, the Company will not, and will cause the Company&rsquo;s subsidiaries to not,
redeem, repurchase or declare any dividend or distribution on any of its capital stock (other than as required under the Series D Certificate
of Designations). In addition, the Company will not issue any preferred stock or issue any other securities that would cause a breach
or default under the Certificate of Designations or Series D Warrants.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Ownership Limitation.
</I>In no event may any Series D Preferred Stock be converted (or Series D Warrants be exercised) and shares of Common Stock be issued
to any holder if after giving effect to the issuance of shares of Common Stock upon such conversion of the Series D Preferred Stock (or
exercise of the Series D Warrants), the holder (together with its affiliates, if any) would beneficially own more than 4.99% of the outstanding
shares of Common Stock, which we refer to herein as the &ldquo;Series D PIPE Blocker&rdquo;. The Series D PIPE Blocker may be raised or
lowered to any other percentage not in excess of 9.99% at the option of the applicable holder of the Series D Preferred Stock (or Series
D Warrants), except that any raise will only be effective upon 61-days&rsquo; prior notice to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exchange Right. </I>If
the Company or any of its Subsidiaries consummates any Subsequent Placement (as defined in the Series D Securities Purchase Agreement)
(other than with respect to Excluded Securities), and a holder elects in writing to the Company to participate in such Subsequent Placement,
each such holder may, at the option of such holder as elected in writing to the Company, exchange all, or any part, of the Series D Preferred
Stock of such holder into the securities in such Subsequent Placement (with the aggregate amount of such securities to be issued in such
exchange equal to such aggregate amount of such securities with a purchase price valued at a 20% premium on the Conversion Amount of the
Series D Preferred Stock delivered by such holder in exchange therefor); provided that any such exchange will be subject to all applicable
Nasdaq restrictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Reservation Requirements.
</I>So long as any Series D Preferred Stock remains outstanding, the Company will at all times reserve at least 150% of the number of
shares of Common Stock as will from time to time be necessary to effect the conversion of all Series D Preferred Stock then outstanding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Conditions Precedent to
Closing</I>: As set forth in the Series D Securities Purchase Agreement, the obligations of each party to consummate the transactions
in connection with the Series D Securities Purchase Agreement are conditioned upon, among other things, customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Series D Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercise Price</I>. The
initial exercise price of the Series D Warrants is $18.448 on a post-reverse split basis. The exercise price is subject to adjustment
for stock splits, combinations and similar events, and, in the event of stock dividends and splits, the number of shares of Common Stock
issuable upon the exercise of the Series D Warrant also will be adjusted so that the aggregate exercise price will be the same immediately
before and immediately after any such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercise Price Adjustments</I>.
If on an Adjustment Date (as defined in the Series D Warrants), the exercise price then in effect is greater than the Market Price then
in effect (the &ldquo;Warrant Adjustment Price&rdquo;), the exercise price will automatically lower to the Warrant Adjustment Price. As
used herein, &ldquo;Market Price&rdquo; means, with respect to any Adjustment Date, the greater of (x) the Floor Price and (y) the lowest
closing price of the Common Stock on the Principal Market on any Trading Day during the five (5) Trading Day period ended on, and including,
the Trading Day ended immediately prior to such applicable Adjustment Date (each, a &ldquo;Market Price Measuring Period&rdquo;). All
such determinations to be appropriately adjusted for any stock dividend, stock split, stock combination, reclassification or similar transaction
that proportionately decreases or increases the Common Stock during such applicable Market Price Measuring Period. Only downward adjustments
will be made.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Adjustments for Dilutive
Issuances or Variable Price Securities</I>. If and whenever the Company grants, issues or sells (or enters into any agreement to grant,
issue or sell), or pursuant to the provisions of the Series D Warrant is deemed to have done any of the foregoing, but excluding any Excluded
Securities granted, issued or sold or deemed to have been granted, issued or sold any shares of Common Stock for a consideration price
per share (the &ldquo;Warrant New Issuance Price&rdquo;) less than a price equal to the exercise price in effect immediately prior to
such granting, issuance or sale (the foregoing a &ldquo;Warrant Dilutive Issuance&rdquo;), then, immediately after such Warrant Dilutive
Issuance, the exercise price then in effect will be reduced to an amount equal to the Warrant New Issuance Price. Notwithstanding the
foregoing, prior to receipt of applicable stockholder approval, no such adjustments shall cause the exercise price to be less than the
floor price of $18.448 on a post-reverse split basis. As of December 5, 2025, such stockholder approval had been obtained.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Additionally, if the Company
grants, issues or sells (or enters into any agreement to grant, issue or sell) securities at a Variable Price (as defined in the Series
D Warrants), the warrant holder shall have the right, but not the obligation, in its sole discretion to exercise the Series D Warrants
at the Variable Price. Notwithstanding the foregoing, prior to receipt of applicable stockholder approval, no such adjustments shall cause
the exercise price to be less than the floor price of $18.448 on a post-reverse split basis. As of December 5, 2025, such stockholder
approval had been obtained.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercise Period</I>. The
Series D Warrants are exercisable beginning on the issuance date and expiring on the third anniversary of the issuance date. The Series
D Warrants require &ldquo;buy-in&rdquo; payments to be made by us for failure to deliver any shares of Common Stock issuable upon exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Cashless Exercise</I>.
If at the time of exercise of the Series D Warrants on or after six months and one day from issuance, there is no effective registration
statement registering the shares of the Common Stock underlying the Series D Warrants, such Series D Warrants may be exercised on a cashless
basis pursuant to their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Purchase Rights; Participation
Rights</I>. If the Company issues options, convertible securities, warrants, shares, or similar securities to holders of the Company shares
of the Common Stock, each Series D Warrant holder has the right to acquire the same as if the holder had exercised its Series D Warrant.
The holders of the Series D Warrants are entitled to receive any dividends paid or distributions made to the holders of the Company&rsquo;s
shares of Common Stock on an &ldquo;as if converted&rdquo; basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Fundamental Transactions</I>.
The Series D Warrants prohibit the Company from entering into specified fundamental transactions unless the successor entity assumes all
of the Company obligations under the Series D Warrants under a written agreement before the transaction is completed. Upon specified corporate
events, a Series D Warrant holder will thereafter have the right to receive upon an exercise such shares, securities, cash, assets or
any other property whatsoever which the holder would have been entitled to receive upon the happening of the applicable corporate event
had the Series D Warrant been exercised immediately prior to the applicable corporate event. When there is a transaction involving specified
changes of control, a Series D Warrant holder will have the right to force the Company to repurchase the holder&rsquo;s Series D Warrant
for a purchase price in cash equal to the Black Scholes value, as calculated under the Series D Warrants, of the then unexercised portion
of the Series D Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Series E Preferred Stock</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The terms of the Certificate
of Designation of Series E Preferred Stock are substantially the same as the terms of the Certificate of Designation of Series D Preferred
Stock, except that each Series E Preferred Stock provides for, each at a post-reverse split basis, (i) an initial Conversion Price of
$19.288, a (ii) Conversion Floor Price of $19.288 and (iii) a Floor Price of $0.298.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>Series E Warrants</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The terms of the Series E
Warrants are substantially the same as the terms of the Series D Warrants, except that each Series E Warrant provides for an initial exercise
price of $19.288 on a post-reverse split basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>PIOs</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The following is a summary
of certain terms and provisions of the preferred investment options (&ldquo;PIOs&rdquo;), issued on August 2, 2023, to certain institutional
investors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Duration and Exercise Price</I>.
Each PIO will have an exercise price equal to $2,554.30 per share on a post-reverse split basis. The PIOs will be exercisable at any time
on or after the date upon the stockholders&rsquo; approval of the transaction and have a term of exercise of five (5) years following
the date of stockholder approval. The exercise price and number of shares of Common Stock issuable upon exercise is subject to appropriate
adjustment in the event of stock dividends, stock splits, subsequent rights offerings, pro rate distributions, reorganizations, a Fundamental
Transaction (as defined in the PIOs) or similar events affecting our common stock and the exercise price.&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Exercisability. </I>The
PIOs will be exercisable, at the option of each holder, in whole or in part, by delivering to the Company a duly executed exercise notice
accompanied by payment in full for the number of shares of our Common Stock purchased upon such exercise (except in the case of a cashless
exercise as discussed below). A holder (together with its affiliates) may not exercise any portion of such holder&rsquo;s PIOs to the
extent that the holder would own more than 4.99% of the outstanding common stock immediately after exercise, except that upon at least
61 days&rsquo; prior notice from the holder to the Company, the holder may increase the amount of ownership of outstanding stock after
exercising the holder&rsquo;s PIOs up to 9.99% of the number of shares of the Company&rsquo;s Common Stock outstanding immediately after
giving effect to the exercise, as such percentage ownership is determined in accordance with the terms of the PIOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Cashless Exercise. </I>If,
at the time a holder exercises its PIOs, a registration statement registering the resale of the Inducement PIO Shares by the holder under
the Securities Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to us
upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole
or in part) the net number of shares of common stock determined according to a formula set forth in the PIOs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Trading Market. </I>There
is no established trading market for the PIOs, and the Company does not expect an active trading market to develop. The Company does not
intend to apply to list the PIOs on any securities exchange or other trading market. Without a trading market, the liquidity of the PIOs
will be extremely limited.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Rights as a Stockholder.
</I>Except as otherwise provided in the PIOs or by virtue of the holder&rsquo;s ownership of shares of the Company&rsquo;s common stock,
such holder of PIOs does not have the rights or privileges of a holder of the Company&rsquo;s common stock, including any voting rights,
until such holder exercises such holder&rsquo;s PIOs. The PIOs will provide that the holders of the PIOs have the right to participate
in distributions or dividends paid on the Company&rsquo;s shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><I>Waivers and Amendments.
</I>The PIOs may be modified or amended or the provisions of the PIOs waived with the Company&rsquo;s and the holder&rsquo;s written consent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Anti-Takeover Effects of Delaware Law and Our
Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Some provisions of Delaware
law, our Amended and Restated Certificate of Incorporation and our Amended and Restated Bylaws could prohibit or delay mergers or other
takeover or change in control attempts and, accordingly, may discourage attempts to acquire us even though such a transaction may offer
our stockholders the opportunity to sell their stock at a price above the prevailing market price.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">These provisions, summarized
below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage
persons seeking to acquire control of us to first negotiate with our Board. We believe that the benefits of the increased protection of
our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the
disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Delaware Anti-Takeover Statute</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to Section
203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be &ldquo;interested stockholders&rdquo;
from engaging in a &ldquo;business combination&rdquo; with a publicly held Delaware corporation for three years following the date these
persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested
stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &ldquo;interested stockholder&rdquo;
is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder
status did own, 15% or more of a corporation&rsquo;s voting stock. Generally, a &ldquo;business combination&rdquo; includes a merger,
asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision
may have an anti-takeover effect with respect to transactions not approved in advance by the Board.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>


<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>Choice of Forum</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation provides that, unless we consent in writing to an alternative forum, to the fullest extent permitted by law,
that derivative actions brought in our name, actions against directors, officers and employees for breach of fiduciary duty and certain
other actions may be brought only in the Court of Chancery in the State of Delaware, except any action (A) as to which the Court of Chancery
in the State of Delaware determines that there is an indispensable party not subject to the jurisdiction of the Court of Chancery (and
the indispensable party does not consent to the personal jurisdiction of the Court of Chancery within ten days following such determination),
(B) which is vested in the exclusive jurisdiction of a court or forum other than the Court of Chancery or (C) for which the Court of Chancery
does not have subject matter jurisdiction. If an action is brought outside of Delaware, the stockholder bringing the suit will be deemed
to have consented to service of process on such stockholder&rsquo;s counsel. Although we believe this provision benefits us by providing
increased consistency in the application of law in the types of lawsuits to which it applies, a court may determine that this provision
is unenforceable, and to the extent it is enforceable, the provision may have the effect of discouraging lawsuits against our directors
and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation provides that the exclusive forum provision will be applicable to the fullest extent permitted by applicable
law, subject to certain exceptions. Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce
any duty or liability created by the Exchange Act or the rules and regulations thereunder. As a result, the exclusive forum provision
will not apply to suits brought to enforce any duty or liability created by the Exchange Act or any other claim for which the federal
courts have exclusive jurisdiction. In addition, our Amended and Restated Certificate of Incorporation provides that, unless we consent
in writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest
extent permitted by law, be the exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities
Act or the rules and regulations promulgated thereunder. We note, however, that there is uncertainty as to whether a court would enforce
this provision and that investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder. Section
22 of the Securities Act creates concurrent jurisdiction for state and federal courts over all suits brought to enforce any duty or liability
created by the Securities Act or the rules and regulations thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Transfer Agent and Registrar</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The transfer agent and registrar
for our Common Stock is Continental Stock Transfer &amp; Trust Company. The Transfer Agent&rsquo;s address is 1 State Street, 30<FONT STYLE="font-size: 10pt"><SUP>th
</SUP></FONT>Floor, New York, New York 10004.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Listing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Common Stock is traded
on The Nasdaq Capital Market under the trading symbol &ldquo;ONCO.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Elimination of Monetary Liability for Officers
and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation incorporates certain provisions permitted under the Delaware General Corporation Law (&ldquo;DGCL&rdquo;)
relating to the liability of directors. The provisions eliminate a director&rsquo;s liability for monetary damages for a breach of fiduciary
duty, including gross negligence, except in circumstances involving certain wrongful acts, such as the breach of director&rsquo;s duty
of loyalty or acts or omissions, which involve intentional misconduct or a knowing violation of law. These provisions do not eliminate
a director&rsquo;s duty of care. Moreover, these provisions do not apply to claims against a director for certain violations of law, including
knowing violations of federal securities law. Our Amended and Restated Certificate of Incorporation also contains provisions to indemnify
the directors, officers, employees or other agents to the fullest extent permitted by the DGCL. We believe that these provisions will
assist us in attracting and retaining qualified individual to serve as directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Indemnification of Officers and Directors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Our Amended and Restated
Certificate of Incorporation also contains provisions to indemnify the directors, officers, employees or other agents to the fullest extent
permitted by the DGCL. These provisions may have the practical effect in certain cases of eliminating the ability of stockholders to collect
monetary damages from directors. We are also a party to indemnification agreements with each of our directors. We believe that these provisions
will assist us in attracting or retaining qualified individuals to serve as our directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_006"></A>SELLING STOCKHOLDER</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The shares of Common Stock
being offered by the Selling Stockholder are those previously issued to the Selling Stockholder, and those issuable to the Selling Stockholder
under the ELOC Purchase Agreement. We are registering the shares of Common Stock in order to permit the Selling Stockholder to offer the
shares for resale from time to time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The table below lists the
Selling Stockholder and other information regarding the beneficial ownership of the shares of Common Stock by the Selling Stockholder.
The second column lists the number of shares of Common Stock beneficially owned by each Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The third column lists the
shares of Common Stock being offered by this prospectus by the Selling Stockholder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The fourth column assumes
the sale of all of the shares offered by the Selling Stockholder pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Under the terms of the ELOC
Purchase Agreement, the Company may not issue shares to the Selling Stockholder under the ELOC Purchase Agreement to the extent that such
issuance would cause the Selling Stockholder, together with its affiliates and attribution parties, to beneficially own a number of shares
of Common Stock which would exceed 4.99% of our then outstanding Common Stock following such issuance, excluding for purposes of such
determination shares of Common Stock issuable under the ELOC Purchase Agreement which have not been issued. The number of shares in the
second and fourth columns do not reflect this limitation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder may
sell all, some or none of its shares in this offering. See &ldquo;<I>Plan of Distribution</I>.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid"><B>Name of Selling Shareholder</B></TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Number of <BR> shares of <BR> Common <BR> Stock <BR> Beneficially <BR> Owned <BR> Prior to <BR> Offering</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Percentage of<BR> shares of<BR> Common<BR> Stock<BR> Beneficially<BR> Owned<BR> Prior to<BR> Offering<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Maximum <BR> Number of <BR> shares of <BR> Common <BR> Stock <BR> to be Sold <BR> Pursuant to <BR> this Prospectus</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Number of <BR> shares of <BR> Common <BR> Stock <BR> Beneficially <BR> Owned <BR> After <BR> Offering</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid; text-align: center"><B>Percentage of <BR> shares of <BR> Common <BR> Stock <BR> Beneficially <BR> Owned <BR> After <BR> Offering<FONT STYLE="font-size: 10pt"><SUP>(1)</SUP></FONT></B></TD>
    <TD STYLE="white-space: nowrap">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 40%">Keystone Capital Partners, LLC<FONT STYLE="font-size: 10pt"><B><SUP>(2)</SUP></B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%">*</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%">*</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%">25,000,000</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%">*</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="text-align: right; width: 9%"><B>4.99</B></TD>
    <TD STYLE="white-space: nowrap; width: 1%"><B>%<FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></B></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD>KCP Fund I, LLC</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">25,000,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right">*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: right"><B>4.99</B></TD>
    <TD STYLE="white-space: nowrap"><B>%<FONT STYLE="font-size: 10pt"><SUP>(3)</SUP></FONT></B></TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">*</TD>
    <TD STYLE="text-align: justify">Less than one percent.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(1)</TD>
    <TD STYLE="text-align: justify">Based on 11,464,572 shares outstanding as of April 24, 2026.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">(2)</TD>
    <TD STYLE="text-align: justify">Represents shares of Common Stock underlying Series C Preferred Stock and Series D Preferred Stock held by this Selling Stockholder, after giving effect to the Maximum Percentage (as defined in the Series C Preferred Stock Certificate of Designations). Keystone Capital Partners LLC is managed by RANZ Group LLC. Frederic Zaino, the Managing Member of RANZ Group LLC, may be deemed to have investment discretion and voting power over the shares held by Keystone Capital Partners LLC. RANZ Group LLC and Mr. Zaino each disclaim any beneficial ownership of these shares. The address of the selling stockholder is 139 Fulton Street, Suite 412, New York, NY 10038.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>(3)</TD>
    <TD STYLE="text-align: justify">Pursuant to the ELOC Purchase Agreement, the Company may not issue or sell any shares of Common Stock to Keystone under the Common Stock Purchase Agreement which, when aggregated with all other shares of Common Stock then beneficially owned by Keystone and its affiliates would result in Keystone beneficially owning more than 4.99% of the outstanding shares of Common Stock.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24pt; text-align: justify; text-indent: -24pt">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_007"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder of
the securities and any of its pledgees, assignees and successors-in-interest may, from time to time, sell any or all of its securities
covered hereby on the principal trading market or any other stock exchange, market or trading facility on which the securities are traded
or in private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following
methods when selling securities:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">an exchange distribution in accordance with the rules of the applicable exchange;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">privately negotiated transactions;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">settlement of short sales;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">in transactions through broker-dealers that agree with the Selling Stockholder to sell a specified number of such securities at a stipulated price per security;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">a combination of any such methods of sale; or</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.25in">&nbsp;</TD>
    <TD STYLE="width: 0.25in">&#9679;</TD>
    <TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder may
also sell securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under
this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Broker-dealers engaged by
the Selling Stockholder may arrange for other brokers-dealers to participate in sales. Broker-dealers may receive commissions or discounts
from the Selling Stockholder (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to
be negotiated, but, except as set forth in a supplement to this Prospectus, in the case of an agency transaction not in excess of a customary
brokerage commission in compliance with Financial Industry Regulatory Authority (&ldquo;FINRA&rdquo;) Rule 2121; and in the case of a
principal transaction a markup or markdown in compliance with FINRA Rule 2121.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Keystone Capital Partners,
LLC is an &ldquo;underwriter&rdquo; within the meaning of Section 2(a)(11) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Keystone Capital Partners,
LLC has represented to us that at no time prior to the date of the ELOC Purchase Agreement has such Selling Stockholder or its agents,
representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is
defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging transaction, which establishes a net short
position with respect to our common stock. Keystone Capital Partners, LLC has agreed that during the term of the ELOC Purchase Agreement,
neither Keystone Capital Partners, LLC nor any of its agents, representatives or affiliates will enter into or effect, directly or indirectly,
any of the foregoing transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Selling Stockholder and
any broker-dealers or agents that are involved in selling the securities may be deemed to be &ldquo;underwriters&rdquo; within the meaning
of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any
profit on the resale of the securities purchased by them may be deemed to be underwriting commissions or discounts under the Securities
Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly
or indirectly, with any person to distribute the securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The Company is required to
pay certain fees and expenses incurred by the Company incident to the registration of the securities. The Company has agreed to indemnify
the Selling Stockholder against certain losses, claims, damages and liabilities, including liabilities under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We have advised the Selling
Stockholder that it is required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions, Regulation M
precludes the Selling Stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution
from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security which is the subject of the distribution
until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a
security in connection with the distribution of that security. All of the foregoing may affect the marketability of the securities offered
by this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_008"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The financial statements
of Onconetix, Inc incorporated in this prospectus by reference to the Annual Report on Form 10-K for the years ended December 31, 2025
and 2024 have been so incorporated in reliance on the reports (which contains an explanatory paragraph regarding the Company&rsquo;s ability
to continue as a going concern) of MaloneBailey, LLP, an independent registered public accounting firm, given on the authority of said
firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_009"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">Ellenoff Grossman &amp; Schole
LLP, New York, New York, will pass upon the validity of the securities offered hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><A NAME="a_010"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">We are subject to the informational
requirements of the Exchange Act and, in accordance therewith, file annual, quarterly and current reports, proxy statements and other
information with the SEC. Our SEC filings are available to the public over the Internet at the SEC&rsquo;s website at <I>www.sec.gov</I>.
Copies of certain information filed by us with the SEC are also available on our website at <I>www.onconetix.com</I>. Our website is not
a part of this prospectus and is not incorporated by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">This prospectus is part of
a registration statement we filed with the SEC. This prospectus omits some information contained in the registration statement in accordance
with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about
us and our consolidated subsidiaries and the securities we are offering. Statements in this prospectus concerning any document we filed
as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified
by reference to these filings. You should review the complete document to evaluate these statements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>


<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">The SEC allows us to incorporate
by reference much of the information we file with the SEC, which means that we can disclose important information to you by referring
you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part
of this prospectus. Because we are incorporating by reference future filings with the SEC, this prospectus is continually updated, and
those future filings may modify or supersede some of the information included or incorporated in this prospectus. This means that you
must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any
document previously incorporated by reference have been modified or superseded. This prospectus incorporates by reference the documents
listed below (File No. 000-52994) and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange
Act (in each case, other than those documents or the portions of those documents not deemed to be filed) between the date of the initial
registration statement and the effectiveness of the registration statement and following the effectiveness of the registration statement
until the offering of the securities under the registration statement is terminated or completed:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026027725/ea0280547-10k_onconetix.htm">Form 10-K</A> for the fiscal year ended December 31, 2025, as filed with the SEC on March 13, 2026;</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(ii)</TD><TD STYLE="text-align: justify">Current Reports on Form 8-K filed on each of <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026015212/ea0276704-8k425_onconet.htm">February
                                                                                    12, 2026</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026033643/ea0283046-8k_onconetix.htm">March
                                                                                    24, 2026</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026034054/ea0283337-8ka1_onconetix.htm">March
                                                                                    25, 2026</A>, <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026034902/ea0283569-8k_onconetix.htm">March
                                                                                    27, 2026</A>,<A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026047577/ea0287604-8k_onconetix.htm"> April
                                                                                    24, 2026</A> and <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026051575/ea0288982-8k_onconetix.htm">May&nbsp;4,&nbsp;2026</A></TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iii)</TD><TD STYLE="text-align: justify">our <A HREF="https://www.sec.gov/Archives/edgar/data/1782107/000121390025036959/ea0240055-def14a_onconetix.htm">Definitive
Proxy Statement</A>, as filed with the SEC on April 30, 2025; and</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 48pt; text-align: justify; text-indent: -24pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(iv)</TD><TD STYLE="text-align: justify">the description of our securities registered under Section
12 of the Exchange Act as filed as <A HREF="http://www.sec.gov/Archives/edgar/data/1782107/000121390026027725/ea028054701ex4-2.htm">Exhibit 4.2</A> on our Annual Report on <A HREF="http://www.sec.gov/ix?doc=/Archives/edgar/data/1782107/000121390026027725/ea0280547-10k_onconetix.htm">Form 10-K</A> for the year ended December 31, 2025, as filed with the SEC on March 13, 2026.</TD>
</TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You may request a copy of
these filings, at no cost, by writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Onconetix, Inc.<BR>
201 E. Fifth Street, Suite 1900<BR>
Cincinnati, Ohio 45202<BR>
(513) 620-4101</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in">You may also access the documents
incorporated by reference in this prospectus through our website at <I>www.onconetix.com</I>. Except for the specific incorporated documents
listed above, no information available on or through our website shall be deemed to be incorporated in this prospectus or the registration
statement of which it forms a part. The information contained on our website is not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><IMG SRC="ea029018501_img1.jpg" ALT=""></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>25,000,000 shares of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Offered by the Selling Stockholder</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>May 7, 2026</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"></P>

<!-- Field: Page; Sequence: 51; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>ea029018501_img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ea029018501_img1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !4 /0# 2(  A$! Q$!_\0
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M'\*?^@BNG^&5@\=G>7[J0LS"-,]PO4_F?TKF/'G_ ".%Y_NI_P"@BM8V]L[
M5H]#U[7K5M3$,EQ&!@.S#) [*#V%1>&]5ETC6[:5'98V<)*F>&4G!R*]:\)
M#PGIN!C]P#7C,O&K.!_S\?\ LU.$^?FBUH![AK.I1Z3I-S?2#(B3(7^\>P_.
MO&'DU7Q/JW.^ZNI22$!X4>W8 5Z=\0U9O"4VWH)$+?3-<E\-9X(M<N8Y"HED
MAQ'GO@Y(%9TO=@YK<$9D_@[Q!I\T++9OO=@$>!\[6]R.GUKTZ.YN-!\,&XU.
M<7%Q;Q;G8#&X]A[]AFMAY$0KO=5W' R<9/I7-^/U=O"-ULSPR%OIN%9N;FTI
M >8RS:KXHU7!WW-S*3MC!^5![=@!4NJ^%M7T2!;FZ@ BR/WD3[@I]_2MSX:2
MP)K=TCD"5X/W>>^#R!7<^*Y8(?"]^;@C8T14 ]V/3]:VE4<9J"6@'/> /$4^
MH)+IE[(9)H5WQ2,<EEZ$'UQ67\40/[6L/^N!_P#0JH?#M7/BN,KT$+[OIQ6A
M\4?^0M8_]<#_ .A5*BE6T#J<YIVD:QXA@$=I&\T%J-JAF 5,\X&>]4HI;S1M
M2WIO@N;=^1T((Z@UZ=\-0/\ A&I#CDW#?R%<+XV 'B[4<?WE_P#016L9\TW"
MV@'L5G=K=:;!='Y5DB60^V1FO'=>UJ]\4:R88=[Q&39;P*>/8_4UZA8*S>"H
M53[QL0!]=E>-:9#<W&H006DOE7#MMC;?LP?KVK.C%7D^P(WKSX?ZQ96+7;>1
M)M7<\<;$L!^7-;7P]\07$ERVD74C2(4+P,QR5QU7Z53/A+QD00;QR#P0;L\U
M;\+^#=7TOQ!;WMTD*PQ[MQ60$]"*<I)P:DTP,'QCH]UINM37-QY?EWDKO%M;
M)Q[U#H/A?4-;7[5:>3Y<,H5O,?!XP?2NE^*7^MTSZ/\ TJ_\,/\ D#7O_7Q_
M[**.=JDF!5^, QX1MP>UTG\C7._!D#^U=4X_Y8I_Z$:Z+XP_\BG!_P!?2?R-
M<_\ !C_D*ZG_ -<4_P#0C7E2?[U'MTU_PGR?F2>.O#@TG5#=V\>+.Z). .$?
MN/QZU#-XPO)O"J:.=WF9V/-GDQ=E^O;Z5W/CW4+2U\.R6\Z+)+<?+$AZ@C^+
M\*\A&,C(R.X]:]BE[\%S+8\0[WX>>&Q--_;-S'^[C.+=2.K=V_#M7I]9'AZ\
MM+[0[66Q4) $"B,?P$=0:UJXJDFY-L0M%%%2!R?BWPDFOPK<6Y6._C&%8]''
M]T_XUY5?:9?Z7.8[RVE@=3P2./J#7T *9)&DJ[7177T89%;4Z[@K;H=SY[>>
M><!'FEE]%9RWZ5T?A[P3J.L3))<1O:V><L[C#,/11_6O6X[&UC;<EM"K>HC
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' **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
